<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77072</article-id><article-id pub-id-type="doi">10.7554/eLife.77072</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>The <italic>CIC-ERF</italic> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-267993"><name><surname>Gupta</surname><given-names>Nehal</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8931-5759</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267994"><name><surname>Song</surname><given-names>Hanbing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-62431"><name><surname>Wu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267995"><name><surname>Ponce</surname><given-names>Rovingaile K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267996"><name><surname>Lin</surname><given-names>Yone K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-267997"><name><surname>Kim</surname><given-names>Ji Won</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-267998"><name><surname>Small</surname><given-names>Eric J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122797"><name><surname>Feng</surname><given-names>Felix Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-198279"><name><surname>Huang</surname><given-names>Franklin W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5447-0436</contrib-id><email>franklin.huang@ucsf.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-266990"><name><surname>Okimoto</surname><given-names>Ross A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4467-8476</contrib-id><email>ross.okimoto@ucsf.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Medicine, University of California</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Helen Diller Family Comprehensive Cancer Center, University of California</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Radiation Oncology, University of California</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>16</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e77072</elocation-id><history><date date-type="received" iso-8601-date="2022-01-14"><day>14</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-10-16"><day>16</day><month>10</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-01-28"><day>28</day><month>01</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.01.26.477820"/></event></pub-history><permissions><copyright-statement>© 2022, Gupta et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Gupta et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77072-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-77072-figures-v1.pdf"/><abstract><p>Human prostate cancer can result from chromosomal rearrangements that lead to aberrant ETS gene expression. The mechanisms that lead to fusion-independent ETS factor upregulation and prostate oncogenesis remain relatively unknown. Here, we show that two neighboring transcription factors, Capicua (<italic>CIC</italic>) and ETS2 repressor factor (<italic>ERF</italic>), which are co-deleted in human prostate tumors can drive prostate oncogenesis. Concurrent <italic>CIC</italic> and <italic>ERF</italic> loss commonly occur through focal genomic deletions at chromosome 19q13.2. Mechanistically, <italic>CIC</italic> and <italic>ERF</italic> co-bind the proximal regulatory element and mutually repress the ETS transcription factor, <italic>ETV1</italic>. Targeting ETV1 in <italic>CIC</italic> and <italic>ERF</italic>-deficient prostate cancer limits tumor growth. Thus, we have uncovered a fusion-independent mode of ETS transcriptional activation defined by concurrent loss of <italic>CIC</italic> and <italic>ERF</italic>.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>prostate cancer</kwd><kwd>Capicua</kwd><kwd>ERF</kwd><kwd>ETS transcription factors</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>K08CA222625</award-id><principal-award-recipient><name><surname>Okimoto</surname><given-names>Ross A</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>5R37CA255453</award-id><principal-award-recipient><name><surname>Okimoto</surname><given-names>Ross A</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA082103</award-id><principal-award-recipient><name><surname>Okimoto</surname><given-names>Ross A</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Benioff Initiative for Prostate Cancer Research Awards</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Feng</surname><given-names>Felix Y</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>NRF- 2020R1A6A3A03039483</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Ji Won</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mutual suppression of <italic>ETV1</italic> by Capicua (CIC) and ETS2 repressor factor (ERF) limits prostate cancer progression.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Prostate cancer (PCa) is the most common solid tumor malignancy in men. Activation of ETS transcription factors (TFs), <italic>ERG</italic>, <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic>, are present in approximately 60% of PCa, underscoring their importance in prostate oncogenesis (<xref ref-type="bibr" rid="bib32">Nelson et al., 2003</xref>). In human PCa, ETS TFs are most commonly activated through gene rearrangements that fuse the androgen responsive gene, <italic>TMPRSS2</italic>, to either <italic>ERG</italic>, <italic>ETV1</italic>, <italic>ETV4</italic>, or <italic>ETV5</italic> (<xref ref-type="bibr" rid="bib44">Sizemore et al., 2017</xref>). Beyond ETS TF fusions, little is known about the underlying molecular mechanisms that lead to increased expression of wildtype (WT) ETS factors, which confer aggressive malignant phenotypes and associate with poor clinical outcomes in fusion negative PCa patients (<xref ref-type="bibr" rid="bib4">Baena et al., 2013</xref>).</p><p>Capicua (CIC) is a High-mobility group (HMG) box TF that silences <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic> through direct target gene repression (<xref ref-type="bibr" rid="bib29">Kim et al., 2021</xref>; <xref ref-type="bibr" rid="bib43">Simón-Carrasco et al., 2018</xref>). <italic>CIC</italic> is frequently altered in human cancer, where it functionally suppresses tumor growth and metastasis (<xref ref-type="bibr" rid="bib2">Ahmad et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Bettegowda et al., 2011</xref>; <xref ref-type="bibr" rid="bib10">Choi et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Dissanayake et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Kim et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Okimoto et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Seim et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Yoshiya et al., 2021</xref>). Notably, in PCa, <italic>CIC</italic> is commonly altered through genomic loss (homozygous and heterozygous deletion) in ~10% of PCa patients (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Grasso et al., 2012</xref>; <xref ref-type="bibr" rid="bib20">Hieronymus et al., 2014</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Robinson et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>) and inactivation of <italic>CIC</italic> de-represses <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic> transcription to promote tumor progression (<xref ref-type="bibr" rid="bib5">Bettegowda et al., 2011</xref>; <xref ref-type="bibr" rid="bib10">Choi et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Kim et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Okimoto et al., 2017</xref>). Leveraging mutational profiling data from multiple PCa cohorts, we previously observed concurrent loss of the ETS2 repressor factor (<italic>ERF</italic>) in <italic>CIC</italic>-deficient prostate tumors (<xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>). Combinatorial loss is most commonly the result of focal deletions (homozygous and heterozygous) at the 19q13.2 locus, where <italic>CIC</italic> and <italic>ERF</italic> are physically adjacent (long and short isoforms of <italic>CIC</italic> are separated from <italic>ERF</italic> by approximately 15 and 30 kb, respectively) to one another in the genome. Since ERF is a transcriptional repressor that binds ETS DNA motifs (<xref ref-type="bibr" rid="bib6">Bose et al., 2017</xref>), we hypothesized that in a fusion independent manner, CIC and ERF cooperate to mutually suppress <italic>ETS</italic> target genes in PCa.</p><p>Through an integrative genomic and functional analysis, we mechanistically show that CIC and ERF directly bind and co-repress a proximal <italic>ETV1</italic> regulatory element limiting PCa progression. Concomitant loss of CIC and ERF de-represses <italic>ETV1</italic>-mediated transcriptional programs and confer <italic>ETV1</italic> dependence in multiple PCa model systems. Thus, we reveal a fusion-independent mechanism to de-repress ETS-mediated PCa progression and potentially uncover a therapeutic approach to target <italic>CIC-ERF</italic> co-deleted PCa.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>CIC is a TF that directly suppresses <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic> TF family members (<xref ref-type="bibr" rid="bib15">Futran et al., 2015</xref>; <xref ref-type="bibr" rid="bib24">Jiménez et al., 2012</xref>; <xref ref-type="bibr" rid="bib29">Kim et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Okimoto et al., 2017</xref>). CIC silences target genes through direct binding of a highly conserved DNA-binding motif (T[G/C]AAT[G/A]AA; <xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib3">Ajuria et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Futran et al., 2015</xref>; <xref ref-type="bibr" rid="bib24">Jiménez et al., 2012</xref>). <italic>CIC</italic> is commonly altered in multiple human cancer subtypes where it suppresses tumor growth and metastasis (<xref ref-type="bibr" rid="bib29">Kim et al., 2021</xref>). <italic>CIC</italic> is located on chromosome 19q13.2, directly adjacent to another transcriptional repressor, namely the <italic>ERF</italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). ERF binds and competes for ETS TF-binding sites (GGAA-motifs) and is frequently altered in human PCa, predominantly through focal deletions (<xref ref-type="bibr" rid="bib6">Bose et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Hou et al., 2020</xref>). We thus hypothesized that concurrent loss of <italic>CIC</italic> and <italic>ERF</italic> may de-repress an ETS-driven transcriptional program that drives PCa progression in a fusion-independent manner. To explore this, we first queried 15 PCa datasets curated on cBioPortal (<xref ref-type="bibr" rid="bib9">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib16">Gao et al., 2013</xref>) and identified a high cooccurrence rate (p&lt;0.001, two-sided Fisher’s exact test [FET]) for <italic>CIC</italic> (10%) and <italic>ERF</italic> (12%) homozygous and heterozygous deletions (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), suggesting that concurrent loss occurs through focal copy number change at the 19q13.2 locus. Through analysis of these clinically annotated specimens, we observed that the <italic>CIC-ERF</italic> co-deletion was present at an increased frequency in PCa with higher Gleason scores and later tumor stages when compared to <italic>CIC-ERF</italic> replete tumors (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In order to understand the association between <italic>CIC</italic> and/or <italic>ERF</italic> alterations in specific PCa cohorts, we stratified published datasets to identify patients that represent primary PCa (<xref ref-type="bibr" rid="bib14">Fraser et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Hieronymus et al., 2014</xref>; ‘ <xref ref-type="bibr" rid="bib8">Cancer Genome Atlas Research Network, 2015</xref>) (PNAS 2014, n=272; Cell 2015, n=333; Nature 2017, n=477 primary PCas) and metastatic castrate resistant prostate cancer (mCRPC) (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Grasso et al., 2012</xref>; <xref ref-type="bibr" rid="bib38">Robinson et al., 2015</xref>) (Nature 2012, n=50; Cell 2015, n=150; PNAS 2019, n=429 mCRPCs). This analysis revealed enrichment of <italic>CIC</italic> and <italic>ERF</italic> alterations including the <italic>CIC-ERF</italic> co-deletion in mCRPC samples (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Importantly, <italic>CIC-ERF</italic> co-deleted tumors clustered as a subgroup when compared to the more well-characterized molecular subsets including <italic>ERG, ETV1, ETV4, SPOP</italic>, and <italic>FOXA1</italic> altered PCas, suggesting a distinct molecular subtype of PCa (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). In order to explore clinical outcomes of patients harboring <italic>CIC-ERF</italic> co-deleted tumors, we performed a survival analysis using the aforementioned PCa datasets and observed significantly worse outcomes in patients who harbored the <italic>CIC-ERF</italic> co-deletion (p=0.001, disease-free survival [DFS] [<italic>ERF-CIC</italic> co-deletion 25 events/90 total; no <italic>ERF-CIC</italic> co-deletion 153 events/910 total] and p=0.01, progression-free survival [PFS] [<italic>ERF-CIC</italic> co-deletion 16 events/52 total; no ERF-CIC co-deletion 77 events/442 total]; <xref ref-type="fig" rid="fig1">Figure 1G</xref>). One limitation of this analysis is that individual studies included overlapping tumors from the same patient (i.e. TCGA PanCancer and Firehose Legacy cohorts). Despite this overlap, we utilized this insight to formulate a hypothesis that <italic>CIC</italic> and <italic>ERF</italic> are co-deleted with increasing frequency in mCRPC and that the <italic>CIC-ERF</italic> co-deletion is associated with worse clinical outcomes in PCa patients.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Capicua (<italic>CIC</italic>) and ETS2 repressor factor (<italic>ERF</italic>) are co-deleted in aggressive prostate cancer (PCa) and associate with worse clinical outcomes.</title><p>(<bold>A</bold>) CIC transcriptionally represses ETV1/4/5. (<bold>B</bold>) The 19q13.2 genomic locus demonstrating the physical location of <italic>ERF</italic> and <italic>CIC</italic>. (<bold>C</bold>) 15 PCa studies (cBioPortal) demonstrating the co-occurrence of <italic>ERF</italic> and <italic>CIC</italic> homozygous and heterozygous deletions. The co-occurrence of <italic>ERF</italic> and <italic>CIC</italic> alterations is highly significant (p&lt;0.001 co-occurrence, Fisher exact test). (<bold>D</bold>) <italic>ERF-CIC</italic> co-deleted PCa stratified by Gleason score and tumor stage. (<bold>E</bold>) Frequency of <italic>ERF</italic> and <italic>CIC</italic> alterations in primary PCa (top) and metastatic castrate resistant prostate cancer (mCRPC; bottom), demonstrating enrichment in mCRPC. (<bold>F</bold>) Onco-print of known genetic drivers (ERG, ETV1, ETV4, SPOP, and FOXA1) of PCa aligned with <italic>CIC</italic> and <italic>ERF</italic> (cBioPortal). <italic>CIC-ERF</italic> co-deleted prostate tumors (red box) do not frequently co-occur with other known oncogenic events. (<bold>G</bold>) Survival analysis performed using 15 PCa datasets from cBioPortal. Disease-free survival (DFS) and progression-free survival (PFS) in patients harboring the <italic>ERF-CIC</italic> co-deletion (red) vs. no <italic>ERF-CIC</italic> co-deletion (blue). p=value, log-rank.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Prostate cancer studies identified in cBioPortal demonstrating the total number of patients, number of patients with shallow or deep deletions in Capicua (CIC)-ETS2 repressor factor (ERF), and the frequency of <italic>CIC-ERF</italic> alterations in each cohort.</title><p>Studies that analyzed predominantly primary prostate cancers (green) and metastatic castrate resistant prostate cancer (mCRPC; yellow) are highlighted.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-77072-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>ETS2 repressor factor (<italic>ERF</italic>)<italic>-</italic>Capicua (<italic>CIC</italic>) co-deletion frequency across 15 prostate cancer studies.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Our initial findings provided rationale to explore the genetic and functional relationship between CIC and ERF. Independently, CIC and ERF have previously been reported to promote malignant phenotypes, including tumor growth and metastasis in multiple human cancer subsets (<xref ref-type="bibr" rid="bib5">Bettegowda et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Bose et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Choi et al., 2015</xref>; <xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Kawamura-Saito et al., 2006</xref>; <xref ref-type="bibr" rid="bib28">Kim et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Bunda et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Okimoto et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Okimoto et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Simón-Carrasco et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Wong et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Yang et al., 2017</xref>). Since our clinical data indicated that combinatorial loss of <italic>CIC</italic> and <italic>ERF</italic> was associated with worse patient outcomes, we hypothesized that <italic>CIC</italic> and <italic>ERF</italic> loss may cooperate to enhance PCa progression. To investigate this, we engineered <italic>ERF</italic>, <italic>CIC</italic>, or both <italic>CIC</italic> and <italic>ERF</italic>-deficient immortalized prostate epithelial cells (PNT2) and performed a series of <italic>in vitro</italic> and <italic>in vivo</italic> experiments to test the combinatorial effect of the <italic>CIC-ERF</italic> co-deletion. Compared to single gene loss of <italic>CIC</italic> or <italic>ERF</italic>, genetic inactivation of both <italic>CIC</italic> and <italic>ERF</italic> increased colony formation (<xref ref-type="fig" rid="fig2">Figure 2A–B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and spheroid formation (<xref ref-type="fig" rid="fig2">Figure 2C–D</xref>) in PNT2 cells. <italic>CIC-ERF</italic> co-deletion also enhanced malignant phenotypes including cellular viability, invasiveness, and migratory capacity in PNT2 (<xref ref-type="fig" rid="fig2">Figure 2E–G</xref>). Additionally, genetic silencing of both <italic>CIC</italic> and <italic>ERF</italic> increased the frequency of subcutaneous tumor xenograft formation in severe-combined immunodeficient (SCID) mice compared to control (<xref ref-type="fig" rid="fig2">Figure 2H</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Thus, our findings demonstrate that the combination of <italic>CIC</italic> and <italic>ERF</italic> loss augments the transformation of PNT2 and promotes malignant phenotypes.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Capicua (<italic>CIC</italic>) and ETS2 repressor factor (<italic>ERF</italic>) loss promote tumor formation and control malignant potential in prostate epithelial cells.</title><p>(<bold>A</bold>) Clonogenic assay comparing prostate epithelial cells (PNT2) with <italic>ERF</italic> KD, <italic>CIC</italic> KO, or <italic>ERF</italic> KD+<italic>CIC</italic> KO compared to control. (<bold>B</bold>) Number of colonies for each condition in (<bold>A</bold>) (n=3). (<bold>C</bold>) Spheroid growth assay using PNT2 cells expressing <italic>ERF</italic> KD, <italic>CIC</italic> KO, <italic>ERF</italic> KD+<italic>CIC</italic> KO vs. control. (<bold>D</bold>) Size of the sphere for each condition in (<bold>C</bold>) (n=6). Error bars represent SD. p Values were calculated using Student’s t test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. (<bold>E</bold>) Cell-titer glo viability assay (n=6), (<bold>F</bold>) transwell assay (n=3), and (<bold>G</bold>) wound healing assay comparing PNT2 <italic>ERF</italic> KD, <italic>CIC</italic> KO, and <italic>ERF</italic> KD+<italic>CIC</italic> KO to control (n=4). Error bars represent SD. p Values were calculated using Student’s t test. (<bold>H</bold>) Bar graph comparing the incidence of PNT2 parental (N=3/10), PNT2 <italic>ERF</italic> KD (5/10), PNT2 <italic>CIC</italic> KO (N=5/10), or PNT2 <italic>ERF</italic> KD+CIC KO (N=6/10) tumor formation in immunodeficient mice. **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Capicua (CIC) and ETS2 repressor factor (ERF) loss enhances tumor formation in prostate epithelial cells (PNT2).</title><p>(<bold>A</bold>) Immunoblot of CIC, ERF, and HSP90 in PNT2 and its different variants. Representative figure; performed in duplicate. Arrows indicate CIC and ERF bands. (<bold>B</bold>) Tumor explants from mice in <xref ref-type="fig" rid="fig2">Figure 2E</xref>.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Full length western blot images of Capicua (CIC), ETS2 repressor factor (ERF) and HSP90 in prostate epithelial cells (PNT2) and its variants with associated raw images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig2-figsupp1-v1.tif"/></fig></fig-group><p>To assess the functional role of CIC and ERF in the context of human PCa progression, we leveraged two genetically annotated, androgen-insensitive PCa cell lines, DU-145 (moderate metastatic potential) and PC-3 (high-metastatic potential). DU-145 cells harbor a loss-of-function ERF mutation (<italic>ERF<sup>A132S</sup></italic>) (<xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>) and express functional WT <italic>CIC</italic>, (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). By comparison, PC-3 cells are deficient in <italic>CIC</italic> (homozygous deletion) and retain functional ERF (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>; <xref ref-type="bibr" rid="bib9">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib16">Gao et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">Seim et al., 2017</xref>). Thus, these cell line models provided isogenic systems to functionally interrogate the role of CIC and ERF in human PCa. Specifically, genetic reconstitution of <italic>ERF</italic> into <italic>ERF</italic>-deficient DU-145 cells decreased colony formation in both <italic>CIC</italic> proficient (parental cells) and <italic>CIC</italic> knockout (KO) conditions (<xref ref-type="fig" rid="fig3">Figure 3A–B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C, D</xref>). While <italic>CIC</italic> loss did not enhance colony formation in <italic>ERF</italic>-deficient DU-145 cells, it significantly increased tumor cell viability, invasion, and migratory capacity compared to control (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Importantly, we observed that ERF expression in <italic>CIC</italic> KO DU-145 cells rescued the CIC-mediated effects on viability and migration/invasion (<xref ref-type="fig" rid="fig3">Figure 3C–D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). These findings indicate that rescuing ERF can partially restore the functional effects of CIC loss in DU-145 cells. To further understand if ERF could suppress tumor growth <italic>in vivo</italic>, we reconstituted WT <italic>ERF</italic> into <italic>CIC</italic> proficient and deficient (<italic>CIC</italic> KO) DU-145 cells and generated subcutaneous xenografts in immunodeficient mice (NU/J). Consistent with our <italic>in vitro</italic> data, <italic>CIC</italic> KO increased the tumor growth rate <italic>in vivo</italic> and genetic reconstitution of WT <italic>ERF</italic> partially suppressed tumor growth compared to DU-145 <italic>CIC</italic> KO cells (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Moreover, genetic reconstitution of <italic>ERF</italic> into <italic>CIC</italic> proficient DU-145 cells suppressed the tumor growth rate <italic>in vivo</italic> (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). We next used PC-3 cells, to further test how ERF and CIC functionally interact in the context of human PCa. We first noted that <italic>ERF</italic> overexpression (OE) or reconstitution of CIC alone decreased PC-3 colony formation, with combinatorial <italic>ERF</italic> OE and <italic>CIC</italic> rescue having the most significant reduction compared to parental PC-3 cells (<xref ref-type="fig" rid="fig3">Figure 3F–G</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F, G</xref>). Moreover, <italic>ERF</italic> and <italic>CIC</italic> expression had a similar impact on decreasing PC-3 viability, invasion, and migratory capacity (<xref ref-type="fig" rid="fig3">Figure 3H–I</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>). Similarly, genetic suppression of <italic>ERF</italic> resulted in a significant increase of colony formation, viability, and invasion compared to parental PC3 cells (<xref ref-type="fig" rid="fig3">Figure 3F–I</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I</xref>). Interestingly, OE of ERF in mice bearing <italic>CIC</italic> deficient PC-3 tumor xenografts decreased tumor growth compared to PC-3 parental and PC-3 cells expressing WT <italic>CIC</italic> (genetic rescue of CIC; <xref ref-type="fig" rid="fig3">Figure 3J</xref>). Since we consistently observed that <italic>ERF</italic> expression could partially rescue the effects of <italic>CIC</italic> loss in PCa, we hypothesized that WT CIC and ERF potentially cooperate to limit PCa progression.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Capicua (CIC) and ETS2 repressor factor (ERF) mutually suppress malignant phenotypes in human prostate cancer (PCa).</title><p>(<bold>A</bold>) Clonogenic assay of DU-145 cells with <italic>ERF</italic> rescue, <italic>CIC</italic> knockout (KO), or <italic>ERF</italic> rescue +<italic>CIC</italic> KO compared to parental control. (<bold>B</bold>) Number of colonies for each condition in (<bold>A</bold>) (n=3). (<bold>C</bold>) Cell-titer glo viability assay (n=6) and (<bold>D</bold>) transwell assay comparing DU-145 parental cells to DU-145 with <italic>ERF</italic> rescue, <italic>CIC</italic> KO, or <italic>ERF</italic> rescue +CIC KO (n=3). p Values were calculated using Student’s t test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Error bars represent SD. (<bold>E</bold>) Relative tumor volume in mice bearing DU-145 parental, DU-145 <italic>ERF</italic>, DU-145 with <italic>CIC</italic> KO, or DU-145 <italic>ERF +CIC</italic> KO xenografts (N=10). p Values were calculated using Student’s t test. *p&lt;0.05. Error bars represent SEM. (<bold>F</bold>) Clonogenic assay in PC-3 cells expressing <italic>ERF</italic> knockdown (KD), <italic>ERF</italic> overexpression (OE), <italic>CIC</italic> OE, or <italic>ERF +CIC</italic> OE compared to control. (<bold>G</bold>) Number of colonies for each condition in (<bold>F</bold>) (n=3). (<bold>H</bold>) Cell-titer glo viability assay (n=6) and (<bold>I</bold>) transwell assay comparing different groups in PC-3 cells (WT, <italic>ERF</italic> KD, <italic>ERF</italic> OE, <italic>CIC</italic> OE, or <italic>ERF +CIC</italic> OE) (n=3). p Values were calculated using Student’s t test. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Error bars represent SD. (<bold>J</bold>) Relative tumor volume in mice bearing PC-3 parental cells, PC-3 <italic>ERF</italic> OE, or PC-3 <italic>CIC</italic> OE (N=10) over 33 days. p Values were calculated using Student’s t test. *p&lt;0.05. Error bars indicate SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>DU-145 and PC-3 prostate cancer cells are well defined model systems to study Capicua (CIC) and ETS2 repressor factor (ERF) function.</title><p>(<bold>A</bold>) Immunoblot of CIC, ERF, and beta-actin in DU-145 cells compared to prostate epithelial cells (PNT2). (<bold>B</bold>) Immunoblot of CIC, ERF, and beta-actin in PC-3 cells compared to PNT2 cells. (<bold>C</bold>) Immunoblot of CIC, ERF, and HSP90 in parental DU-145 cells and engineered DU-145 different variants. Representative figure; performed in duplicate. (<bold>D</bold>) Relative ERF mRNA expression in DU-145 parental, ERF rescue, CIC knockout (KO), and ERF rescue +CIC KO (n=3), Student’s t-test, ***p&lt;0.001, and ****p&lt;0.0001. (<bold>E</bold>) Wound healing assay in DU-145 cells with <italic>ERF</italic> rescue, <italic>CIC</italic> KO, or <italic>ERF</italic> rescue +<italic>CIC</italic> KO compared to parental (n=2). (<bold>F</bold>) <italic>CIC</italic> mRNA expression in PC-3 parental, PC-3 <italic>CIC</italic> overexpression (OE), and PC-3 (<italic>ERF +CIC</italic>) OE (n=3). p Value = ****p&lt;0.0001 (<bold>G</bold>) Relative <italic>ERF</italic> mRNA expression in PC-3 parental, PC-3 <italic>ERF</italic> OE, PC-3 (<italic>ERF +CIC</italic>) OE, and PC-3 <italic>ERF</italic> knockdown (KD) (n=3). p Value = *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001. (<bold>H</bold>) Wound healing assay in PC-3 cells expressing <italic>ERF</italic> OE, <italic>CIC</italic> OE, (<italic>ERF +CIC</italic>) OE, or <italic>ERF</italic> KD compared to control (n=6). (<bold>I</bold>) Immunoblot of ERF and HSP90 in PC-3 cells with <italic>ERF</italic> KD.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Full-length western blot images of basal levels of Capicua (CIC), ETS2 repressor factor (ERF), and β-actin in prostate epithelial cells (PNT2), DU145, and PC3 cells and associated raw images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Full-length western blot images of CIC, ETS2 repressor factor (ERF), and HSP90 in DU145 cells with its variants and associated raw images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata3"><label>Figure 3—figure supplement 1—source data 3.</label><caption><title>Full-length western blot images of ETS2 repressor factor (ERF) and HSP90 in PC3 cells with its variants and associate raw images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig3-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig3-figsupp1-v1.tif"/></fig></fig-group><p>In order to mechanistically define how CIC and ERF (two TFs with known repressor function) were interacting to functionally regulate PCa, we performed chromatin immunoprecipitation followed by sequencing (ChIP-Seq) using a validated CIC antibody (<xref ref-type="bibr" rid="bib31">Lin et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Okimoto et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Okimoto et al., 2017</xref>) in PNT2, and compared this to a publicly available ERF ChIP-Seq dataset in VCaP PCa cells (<xref ref-type="bibr" rid="bib6">Bose et al., 2017</xref>), we were unsuccessful at pulling down ERF in PNT2 cells. This analysis identified 178 high-confidence (False-discovery rate (FDR) ≤0.05) CIC peaks that mapped to 130 annotated genes including known targets, <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic>. Globally, CIC peaks were localized to distinct genomic regions including promoters (38.6%), untranslated regions (UTRs) (1.14%), introns (19.9%), and distal intergenic regions (38.64%). Interestingly, the distribution of ERF peaks was similar to CIC, with 32.8% in promoters, 1.2% in UTRs, 29.2% intronic, and 33.8% in distal intergenic regions (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Next, through a comparative ChIP-Seq analysis (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), we identified 91 shared CIC and ERF target genes. Importantly, we focused on genes with shared CIC- and ERF-binding sites to potentially explain the functional cooperativity that we observed in our prior studies. In order to narrow down potential candidates, we performed Functional Clustering Analyses through the DAVID bioinformatics database (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov">https://david.ncifcrf.gov</ext-link>) (<xref ref-type="bibr" rid="bib22">Huang et al., 2009</xref>; <xref ref-type="bibr" rid="bib41">Sherman et al., 2022</xref>) using the 91 shared CIC and ERF target genes (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Among these putative CIC and ERF targets, the <italic>PEA3</italic> (<italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic>) TFs (known oncogenic drivers in PCa; <xref ref-type="bibr" rid="bib4">Baena et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="bib33">Oh et al., 2012</xref>) were found to be the most highly enriched family. These findings suggested that CIC and ERF may co-regulate PEA3 family members through direct transcriptional control.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Capicua (CIC) and ETS2 repressor factor (ERF) cooperatively bind an <italic>ETV1</italic> regulatory element to suppress <italic>ETV1</italic> expression and transcriptional activity.</title><p>(<bold>A</bold>) Percentage of CIC and ERF peaks located in defined genomic regions. (<bold>B</bold>) Schematic algorithm to identify shared CIC and ERF target genes in prostate cells (top). Functional Clustering Analysis of the 91 shared CIC and ERF target genes using DAVID (bottom table). (<bold>C</bold>) <italic>ETV1</italic> mRNA expression in prostate epithelial cells (PNT2) (<italic>CIC-ERF</italic>-replete) cells with <italic>ERF</italic> knockdown (KD), <italic>CIC</italic> knockout (KO), or <italic>ERF</italic> KD +<italic>CIC</italic> KO (n=3). (<bold>D</bold>) Schematic of CIC and ERF DNA-binding motifs in the <italic>ETV1</italic> promoter. (<bold>E</bold>) Chromatin immunoprecipitation (ChIP)-PCR from PNT2 cells showing CIC occupancy on the <italic>ETV1</italic> promoter. (<bold>F–G</bold>) ChIP-PCR with ERF occupancy on the <italic>ETV1</italic> promoter. (<bold>H</bold>) <italic>ETV1</italic> mRNA expression in DU-145 (ERF-deficient) cells with <italic>ERF</italic> rescue, <italic>CIC</italic> KO, or <italic>ERF</italic> rescue +<italic>CIC</italic> KO (n=3). <italic>ETV1</italic> mRNA expression in PC-3 cells with (<bold>I</bold>) <italic>ERF</italic> KD (n=3) and (<bold>J</bold>) <italic>ERF</italic> overexpression (OE) (n=3). p Values were calculated using Student’s t test. *p&lt;0.05, **p&lt;0.01, and ****p&lt;0.0001. Error bars represent SD. Performed in triplicate. (<bold>K</bold>) <italic>ETV1</italic> luciferase promoter assay in 293T cells comparing Empty vector (EV) with <italic>ERF</italic> OE (n=6). Student’s t test, *p&lt;0.05. Error bars represent SD. (<bold>L</bold>) Single sample gene set enrichment analysis (ssGSEA) alignments comparing gene expression patterns in PNT2 cells with <italic>ERF</italic> KD and <italic>CIC</italic> KO. IC = information coefficient.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Full-length PCR gel images of <italic>ETV1</italic> after Capicua (CIC) pull down in prostate epithelial cells (PNT2).</title><p>Cropped images and description shown in <xref ref-type="fig" rid="fig4">Figure 4E</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Full-length PCR gel images of <italic>ETV1</italic> after ETS2 repressor factor (ERF) pull down in prostate epithelial cells (PNT2).</title><p>Cropped images and description shown in <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Full-length PCR gel images of <italic>ETV1</italic> after ETS2 repressor factor (ERF) pull down in DU-145 cells.</title><p>Cropped images and description shown in <xref ref-type="fig" rid="fig4">Figure 4G</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig4-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>ETV1, but not ETV4 or ETV5, is a transcriptional target of both ETS2 repressor factor (ERF) and Capicua (CIC).</title><p>(<bold>A–C</bold>) Relative <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic> mRNA expression in prostate epithelial cells (PNT2) parental and PNT2 CIC knockout (KO) cells (n=3). (<bold>D–F</bold>) Relative <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic> mRNA expression in PNT2 parental and PNT2 <italic>ERF</italic> knockdown (KD) +<italic>CIC</italic> KO cells (n=3). (<bold>G</bold>) Relative <italic>ERF</italic>, (<bold>H</bold>) <italic>ETV1</italic>, (<bold>I</bold>) <italic>ETV4</italic>, and (<bold>J</bold>) <italic>ETV5</italic> mRNA expression in parental PNT2 and PNT2 <italic>ERF</italic> KD cells (n=3). (<bold>K</bold>) Co-immunoprecipitation using GFP-tagged ERF (pulldown) and immunoblotting for ERF and CIC. (<bold>L</bold>) Co-immunoprecipitation using Myc-tagged CIC (pulldown) and immunoblotting for ERF and CIC. (<bold>M</bold>) <italic>ETV1</italic> chromatin immunoprecipitation (ChIP)-PCR fold enrichment of CIC compared to IgG control in PNT2 cells (n=3). (<bold>N</bold>) <italic>ETV1</italic> ChIP-PCR fold enrichment of ERF compared to IgG control in PNT2 cells (n=3). (<bold>O</bold>) Gene Desert quantitative PCR (Active Motif Negative control) comparing CIC and ERF to IgG control. (<bold>P</bold>) Gene Desert quantitative PCR (Active Motif Negative control) comparing CIC, ERF, and IgG to input control. Relative (<bold>Q</bold>) <italic>ERF</italic>, (<bold>R</bold>) <italic>ETV1</italic>, (<bold>S</bold>) <italic>ETV4</italic>, and (<bold>T</bold>) <italic>ETV5</italic> mRNA expression in parental DU-145 and DU-145 ERF cells (n=3). p Values for all figures = *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001. Error bars represent SD.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Co-immunoprecipitation using GFP-tagged ETS2 repressor factor (ERF) and immunoblotting for Capicua (CIC; bottom panel) and ETS2 repressor factor (ERF; top panel) with associated raw images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Co-immunoprecipitation using myc-tagged Capicua (CIC) and immunoblotting for ETS2 repressor factor (ERF; top panel) and CIC (bottom panel) with associated raw images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77072-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig4-figsupp1-v1.tif"/></fig></fig-group><p>In order to further identify how CIC and/or ERF impact <italic>PEA3</italic> TF expression, we performed quantitative real time polymerase chain reaction (qRT-PCR) in PNT2 cells, assessing <italic>ETV1</italic>, <italic>ETV4</italic>, or <italic>ETV5</italic> mRNA levels in response to genetic silencing of <italic>CIC</italic> and/or <italic>ERF</italic>. As expected, <italic>CIC</italic> KO and/or combinatorial <italic>CIC</italic> and <italic>ERF</italic> loss in PNT2 cells (<italic>ERF</italic> and <italic>CIC</italic> WT) consistently increased <italic>ETV1, ETV4, and ETV5</italic> levels compared to control (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-F</xref>). In contrast, genetic silencing of <italic>ERF</italic> consistently increased <italic>ETV1</italic> mRNA expression, but not <italic>ETV4</italic> or <italic>ETV5</italic> (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G-J</xref>). These findings indicated that <italic>ETV1</italic> may be a shared transcriptional target of CIC and ERF in prostate cells. In order to test a potential proteomic interaction between CIC and ERF, we performed co-immunoprecipitation (Co-IP) experiments but did not observe binding when either ERF or CIC was pulled down in HEK293T cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1K-L</xref>). This led us to hypothesize that CIC and ERF may potentially bind (but not interact) to distinct regions along the <italic>ETV1</italic> regulatory element. To explore this, we first localized CIC (TGAATGGA) and ERF (GGAA) DNA binding motifs within the proximal upstream regulatory element of <italic>ETV1</italic> and independently confirmed CIC and ERF occupancy of the <italic>ETV1</italic> promoter through ChIP-PCR (<xref ref-type="fig" rid="fig4">Figure 4D–G</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1M, P</xref>). To extend these findings into the context of PCa, we reconstituted <italic>ERF</italic> in <italic>ERF</italic> deficient DU-145 cells and this consistently decreased <italic>ETV1</italic> expression (not <italic>ETV4</italic> or <italic>ETV5</italic>) in both CIC proficient and CIC deficient settings (<xref ref-type="fig" rid="fig4">Figure 4H</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1Q-T</xref>). Moreover, <italic>ERF</italic> Knockdown (KD) or <italic>ERF</italic> OE in <italic>CIC</italic> deficient PC-3 cells increased and decreased <italic>ETV1</italic> mRNA expression, respectively (<xref ref-type="fig" rid="fig4">Figure 4I–J</xref>). Since <italic>ETV1</italic> is a known target of CIC (<xref ref-type="bibr" rid="bib12">Dissanayake et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Jiménez et al., 2012</xref>), we focused on further validating <italic>ETV1</italic> as a molecular target of ERF. To this end, we engineered a <italic>ETV1</italic> luciferase based promoter assays and observed a decrease in luciferase activity following ERF expression in 293T cells (<xref ref-type="fig" rid="fig4">Figure 4K</xref>). These genetic tools further validate that ERF can suppress <italic>ETV1</italic> expression through direct transcriptional silencing of the <italic>ETV1</italic> promoter and identifies <italic>ETV1</italic> as an ERF target.</p><p>Consistent with a repressor function, ERF loss was previously shown to transcriptionally associate with ETV1-regulated gene set signatures (<xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>). Yet it remains unclear if ERF can directly regulate <italic>ETV1</italic> and how combinatorial loss of CIC and ERF controls ETV1-mediated (or other ETS family members) transcriptional programs. To explore this, we generated a signature gene set of upregulated genes from our dual <italic>CIC</italic> and <italic>ERF</italic> deficient PNT2 cells (<italic>ERF</italic> KD +<italic>CIC</italic> KO) and projected the Cancer Genome Atlas PCa (TCGA-PRAD) dataset onto the transcriptional space of these signature gene sets using the ssGSEA module (Version 10.0.9) on GenePattern (<xref ref-type="bibr" rid="bib37">Reich et al., 2006</xref>). We found that <italic>CIC</italic> and <italic>ERF</italic> loss were significantly associated with the <italic>ETV1</italic>-regulated gene set (Information coefficient (IC)=0.619, p=0.0009), but was anti-correlated with the <italic>TMPRSS2-ERG</italic> fusion signature gene set (<xref ref-type="bibr" rid="bib40">Setlur et al., 2008</xref>; <xref ref-type="fig" rid="fig4">Figure 4L</xref>, IC = –0.45, p=0.0009). Thus, the enrichment of the <italic>ETV1</italic>-regulated gene set signature was shared between <italic>ERF</italic> loss alone (<xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>) and <italic>CIC-ERF</italic> dual suppression (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). In contrast, combinatorial <italic>CIC</italic> and <italic>ERF</italic> loss negatively correlated with the <italic>TMPRSS2-ERG</italic> fusion signature gene set, which was not consistent with our prior studies using <italic>ERF</italic> KD alone (<xref ref-type="bibr" rid="bib23">Huang et al., 2017</xref>). These findings led us to hypothesize that the dual suppression of <italic>CIC</italic> and <italic>ERF</italic> may increase ETV1-mediated transcriptional programs in PCa. This was supported by two major lines of experimental and conceptual evidence including: (1) dual suppression of <italic>ETV1</italic> expression and ETV1 mediated transcriptional output by CIC and ERF; and (2) the majority of tumors derived from PCa patients that harbor <italic>ERF</italic> deletions also contain deletions in <italic>CIC</italic>.</p><p>In order to demonstrate enhanced survival dependence on ETV1 in PCa cells, we genetically silenced <italic>CIC</italic> in ERF-deficient DU-145 cells and assessed drug sensitivity to an ETV1 inhibitor (BRD32048) (<xref ref-type="bibr" rid="bib36">Pop et al., 2014</xref>). We validated the pharmacologic effect of ETV1 inhibition (BRD32048) through suppression of known downstream target genes (<italic>ATAD2</italic> and <italic>ID2)</italic> using qPCR in LNCaP cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A-C</xref>). Since BRD32048 was previously shown to decrease invasiveness in ETV1-fusion positive PCa cells (LNCaP), but not significantly impact tumor cell viability, we unexpectedly observed that silencing <italic>CIC</italic> in DU-145 cells mildly enhanced sensitivity to BRD32048 (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). To further confirm these findings and to mitigate potential off-target effects, we silenced <italic>ETV1</italic> using siRNA in PC3 and DU-145 cells expressing Crispr-based sgRNA targeting <italic>CIC</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D-F</xref>). Consistent with our pharmacologic studies, the viability of DU-145 <italic>CIC</italic> KO cells was decreased upon genetic <italic>ETV1</italic> inhibition (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Similarly, pharmacologic and genetic ETV1 inhibition decreased invasiveness of CIC deficient DU-145 cells (<xref ref-type="fig" rid="fig5">Figure 5C–D</xref>). These findings indicate that loss of CIC in ERF deficient PCa cells can potentially modulate the sensitivity to ETV1-directed therapies. To expand these findings, we also consistently observed a decrease in viability and invasiveness upon ETV1 inhibition (BRD32048) in PNT2 cells with dual <italic>ERF</italic> and <italic>CIC</italic> suppression and in PC-3 cells with <italic>ERF</italic> KD (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A-J</xref>). These <italic>in vitro</italic> findings indicate that ETV1 inhibition in <italic>CIC</italic> and <italic>ERF</italic> deficient prostate cells can suppress invasion and potentially limit viability. Further studies targeting ETV1 in patient derived specimens that harbor endogenous <italic>CIC-ERF</italic> co-deletions is warranted. Collectively, our data indicate that CIC and ERF may cooperate to silence ETV1 transcriptional programs, limiting ETV1-mediated PCa progression.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Combinatorial CIC and ETS2 repressor factor (ERF) loss can modulate ETV1 inhibitor sensitivity in prostate cells.</title><p>(<bold>A</bold>) DU-145 cells were transfected with either siScramble (siSCM) or si<italic>CIC</italic>. After 48 hr, BRD32048 (ETV1 inhibitor) was added to both the transfected groups at the defined concentrations (0 μM, 25 μM, 50 μM). After 24 hr of BRD32048 treatment, cells were replated for crystal violet assay (0.4%) and images were taken and analyzed after 5 days (n=3). siCIC was compared to siSCRM conditions in each respective drug concentration. (<bold>B</bold>) Crystal violet viability assay (n=3). si<italic>ETV1</italic> groups were compared to siSCRM control groups +/- <italic>CIC</italic> expression (sgCtrl, sgCIC1, or sgCIC2). (<bold>C</bold>) DU-145 cells were transfected with either siScramble (siSCM) or si<italic>CIC</italic>. After 48 hr, BRD32048 was added to the transfected groups at defined concentrations (0 μM or 50 μM). Transwell invasion assays (n=3) were performed 24 hr after the addition of BRD32048. siCIC was compared to siSCRM in the 0 μM and 50 μM concentration groups. (<bold>D</bold>) Transwell invasion assays (n=3) comparing si<italic>ETV1</italic> to siSCRM control +/-CIC expression (sgCtrl, sgCIC1, or sgCIC2). p value = *p&lt;0.05, **p&lt;0.01 for all figures. Error bars represent SD.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Validation of ETV1 chemical (BMS32048) and genetic inhibition in prostate cancer cells.</title><p>(<bold>A–C</bold>) Relative <italic>ETV1</italic>, <italic>ATAD2,</italic> and <italic>ID2</italic> mRNA expression in LNCaP cells with or without BMS32048 (ETV1 inhibitor) treatment (n=3). (<bold>D</bold>) Relative <italic>ETV1</italic> mRNA expression in PC-3 cells, (<bold>E</bold>) DU-145 +sgCIC1 and (<bold>F</bold>) DU-145 +sgCIC2 with or without si<italic>ETV1</italic> (n=3). p values for all figures = **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>CIC and ETS2 repressor factor (ERF) expression modulate sensitivity to ETV1 inhibitor, BRD32048.</title><p>(<bold>A</bold>) BRD32048 treatment of PNT2 cells expressing si<italic>CIC</italic> and si<italic>ERF</italic> compared to siSCRM control. (<bold>B</bold>) Relative density of crystal violet assays performed in (<bold>A</bold>) (n=3). (<bold>C</bold>) Transwell assay comparing BRD32048 treated PNT2 cells (n=3). BRD32048 (0 μM) columns were set to ‘1’ in the siSCRM and si<italic>ERF +siCIC</italic> groups for relative comparison in (<bold>B–C</bold>). (<bold>D</bold>) Relative density of crystal violet assays performed in (<bold>A</bold>) (n=3). (<bold>E</bold>) Transwell assay comparing BRD32048 treated PNT2 cells (n=3). siSCRM column (0 µM) was set to ‘1’ for relative comparison to other groups in (<bold>D–E</bold>). (<bold>F</bold>) BRD32048 treatment of PC-3 cells expressing si<italic>ERF</italic> compared to siSCRM control. (<bold>G</bold>) Relative density of crystal violet assays performed in (<bold>F</bold>) (n=3). (<bold>H</bold>) Transwell assay comparing BRD32048 treated PC-3 cells (n=3). BRD32048 (0 μM) columns were set to ‘1’ in the siSCRM and si<italic>ERF</italic> groups for relative comparison in (<bold>G–H</bold>). (<bold>I</bold>) Relative density of crystal violet assays performed in (<bold>F</bold>) (n=3). (<bold>J</bold>) Transwell assay comparing BRD32048 treated PC-3 cells (n=3). siSCRM column (0 µM) was set to ‘1’ for relative comparison to other groups in (<bold>I–J</bold>). Students t-test, p values *p&lt;0.05, **p&lt;0.01 for all figures.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-fig5-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Molecular and functional subclassification of human PCa has revealed a dependence on ETS family TFs including ERG, ETV1, ETV4, and ETV5 (<xref ref-type="bibr" rid="bib13">Feng et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Oh et al., 2012</xref>). The predominant mode of ETS activation in PCa is through chromosomal rearrangements that fuse <italic>ERG, ETV1, ETV4, and ETV5</italic> to the androgen-regulated <italic>TMPRSS2</italic> gene, leading to fusion oncoproteins that drive oncogenesis (<xref ref-type="bibr" rid="bib11">Clark and Cooper, 2009</xref>; <xref ref-type="bibr" rid="bib13">Feng et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Helgeson et al., 2008</xref>; <xref ref-type="bibr" rid="bib46">Tomlins et al., 2006</xref>; <xref ref-type="bibr" rid="bib45">Tomlins et al., 2005</xref>). Interestingly, recent data indicate that <italic>ETV1</italic>, <italic>ETV4</italic>, and <italic>ETV5</italic> are upregulated in a fusion-independent manner and are associated with poor clinical outcomes in PCa patients (<xref ref-type="bibr" rid="bib4">Baena et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Hermans et al., 2008</xref>). Our study focused on understanding the molecular mechanisms that drive fusion-independent upregulation of ETS family members and we reveal a new molecular subclass of PCa defined by a co-deletion of two TFs, <italic>CIC</italic> and <italic>ERF</italic>.</p><p>CIC is a TF that directly silences <italic>ETV1, ETV4, and ETV5</italic> transcription through direct repression at proximal regulatory sites (<xref ref-type="bibr" rid="bib24">Jiménez et al., 2012</xref>). We observed that in ~10–12% of human PCa, <italic>CIC</italic> and <italic>ERF</italic> are co-deleted through focal homozygous or heterozygous deletions. It has been recently shown that ERF competes for ETS DNA binding motifs and our studies identify cooperative regulation of key target genes between CIC and ERF. Specifically, through ChIP-Seq analysis coupled with a series of <italic>in vitro</italic> and <italic>in vivo</italic> studies, we identify a coordinated binding of CIC and ERF to the proximal <italic>ETV1</italic> regulatory element that physically and functionally regulates ETV1 expression. Therefore, we reveal <italic>ETV1</italic> as a novel ERF target gene. Rescuing <italic>ERF</italic> in <italic>CIC</italic> deficient PCa cells decreases <italic>ETV1</italic> expression and limits malignant phenotypes including viability, migration and invasion.</p><p>The 19q13.2 locus contains <italic>CIC</italic> and <italic>ERF,</italic> which are physically adjacent and oriented in opposing directions. The long and short isoforms of <italic>CIC</italic> are separated from <italic>ERF</italic> by ~15 and 30 kb, respectively. Thus, future studies directed at defining the genome topology and epigenetic states, both within and around this highly conserved region are warranted. In particular, studies aimed at mapping topology associated domains and key histone marks can potentially reveal shared upstream regulatory elements including enhancers or superenhancers that may co-regulate <italic>CIC</italic> and <italic>ERF</italic> in concert. These findings could reveal non-genetic mechanisms to functionally regulate <italic>CIC</italic> and <italic>ERF</italic> expression in a coordinated fashion.</p><p>Beyond PCa, we and others have observed that <italic>CIC</italic> and <italic>ERF</italic> are co-deleted in a subset of stomach adenocarcinoma (<xref ref-type="bibr" rid="bib30">LeBlanc et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Okimoto et al., 2017</xref>). Thus, combined <italic>CIC</italic> and <italic>ERF</italic> loss are not entirely specific for PCa. We speculate that since prostate (<xref ref-type="bibr" rid="bib4">Baena et al., 2013</xref>) and potentially stomach adenocarcinoma (<xref ref-type="bibr" rid="bib26">Keld et al., 2011</xref>) are highly dependent on PEA3 transcriptional dysregulation to enhance tumor progression, the dual loss of <italic>CIC</italic> and <italic>ERF</italic> may, in part, represent an alternative mode to de-repress ETS mediated transcriptional programs in these cancer subsets.</p><p>The use of ETV1 inhibitors has been limited to preclinical studies (<xref ref-type="bibr" rid="bib36">Pop et al., 2014</xref>). These studies have largely focused on direct targeting of ETV1 fusion oncoproteins in PCa (<xref ref-type="bibr" rid="bib36">Pop et al., 2014</xref>). Our findings indicate that patients with <italic>CIC-ERF</italic> deficient PCa may have a survival dependence on ETV1 and that these patients may potentially benefit from ETV1 directed therapies. A limitation of this targeted approach in PCa patients is that we did not find a statistically significant difference in <italic>ETV1</italic> transcript levels in <italic>CIC-ERF</italic> co-deleted tumors compared to <italic>CIC-ERF</italic> replete tumors in the TCGA-PRAD (n=455) dataset. One potential explanation is that <italic>ETV1</italic> is commonly upregulated in human PCas through mechanisms beyond <italic>CIC-ERF</italic> loss. Thus, while our data support the upregulation and potential induced dependence on ETV1 in our <italic>CIC-ERF</italic> deficient systems, it remains unclear if this will translate beyond our cell-line based models into PCa patients that harbor <italic>CIC-ERF</italic> co-deletions. Thus, larger studies that aim to evaluate: (1) <italic>ETV1</italic> mRNA and protein expression levels; (2) the biological significance of ETV1 function; and (3) the clinical application of ETV1 inhibitors in patients with endogenous <italic>CIC-ERF</italic> co-deleted tumors (compared to <italic>CIC-ERF</italic> WT tumors) is warranted in this subset of PCa. Collectively, we have uncovered a molecular subset of PCa defined by a co-deletion of <italic>CIC</italic> and <italic>ERF</italic> and further demonstrate a mechanism-based strategy to potentially limit tumor progression through ETV1 inhibition in this subset of human PCa.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene<break/>CIC (<italic>Homo sapiens)</italic></td><td align="left" valign="bottom"><italic>CIC</italic></td><td align="left" valign="bottom">Pubmed gene database</td><td align="left" valign="bottom">Gene ID:<break/>23152</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>ERF (<italic>Homo sapiens)</italic></td><td align="left" valign="bottom"><italic>ERF</italic></td><td align="left" valign="bottom">Pubmed gene database</td><td align="left" valign="bottom">Gene ID: 2077</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene<break/>ETV1 (<italic>Homo sapiens)</italic></td><td align="left" valign="bottom"><italic>ETV1</italic></td><td align="left" valign="bottom">Pubmed gene database</td><td align="left" valign="bottom">Gene ID:<break/>2115</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line maintained in DMEM with 10% FBS and 1% PSN</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">PNT2</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line maintained in DMEM with 10% FBS and 1% PSN</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">DU-145</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line maintained in RPMI with 10% FBS and 1% PSN</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">PC3</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cell line maintained in RPMI with 10% FBS and 1% PSN</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">ERF shRNA #1</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">CAT# TRCN000001391<break/>TRCN0000013912</td><td align="left" valign="bottom">Lentiviral construct to transfect and express<break/>ERF shRNA.</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">sgRNAs</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">CAT#74959 and #74953</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">Lentiviral GFP-tagged ERF</td><td align="left" valign="bottom">GeneCopoeia</td><td align="left" valign="bottom">CAT# EX-S0501-Lv122</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">CIC-Myc-tag plasmid</td><td align="left" valign="bottom">Origene</td><td align="left" valign="bottom">CAT#: RC215209</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to ETV1<break/>SMARTpool</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">CAT#<break/>L-003801-00-0005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to CIC<break/>SMARTpool</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">CAT#<break/>L-015185-01-0005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CIC<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">CAT#<break/>PA146018</td><td align="left" valign="bottom">WB (1:1000)<break/>For ChIP</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ERF<break/>(Rabbit monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">CAT#<break/>PA530237</td><td align="left" valign="bottom">WB (1:1000)<break/>For ChIP</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HSP90<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">CAT# 4874 S</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Actin<break/>(Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">CAT# 4970 S</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ETV1-CIC-Forward-1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ChIP-PCR primers</td><td align="left" valign="bottom">5’ CAGGACAAAGAGGAGGCAGCGAGCTG-3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ETV1-CIC-Reverse-1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ChIP-PCR primers</td><td align="left" valign="bottom">5’ GTTTATTGCTGACCCCTCAGCGCTCCGC 3’</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ETV1-ERF-Forward-1-</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ChIP-PCR primers</td><td align="left" valign="bottom">5’-CCAGGTCCGGGGTTGAGTGCTGTGC- 3</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ETV1-ERF-Reverse-1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ChIP-PCR primers</td><td align="left" valign="bottom">5’-CATTTGTGACCAGAACTAGTGACC-3</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">ETV1 promoter</td><td align="left" valign="bottom">SwitchGear Genomics</td><td align="left" valign="bottom">Product ID: S720645</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Empty promoter</td><td align="left" valign="bottom">SwitchGear Genomics</td><td align="left" valign="bottom">Product ID: S790005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BRD32048</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat#: SML1346</td><td align="left" valign="bottom">ETV1 inhibitor</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell lines, drug, and reagents</title><p>Cell lines were cultured as recommended by the American Type Culture Collection (ATCC) or Sigma. DU-145, PC-3, and HEK293T cells were purchased and authenticated (STR profiling) by ATCC. PNT2 cells were purchased and authenticated (STR profiling) by Sigma. All cell lines were tested for mycoplasma using the e-myco PLUS PCR detection kit (Boca Scientific, Cat#25237). HEK293T cells are human embryonic kidney cells which are commonly used for transfection. PNT2 ERF KD (shERFA1, shERFB1), PNT2 CIC KO (sgCIC1, sgCIC2) and PNT2 ERF KD +CIC KO were derived from parental PNT2 cells. shRNAs targeting ERF to develop PNT2 shERFA1 and PNT2 shERFB1 were obtained from Sigma-Aldrich: TRCN000001391, TRCN0000013912. Puromycin (1 μg/ml) was used as a selection reagent. Two sgRNAs targeting CIC were previously validated and were gifts from William Hahn, Addgene (#74959 and #74953). These sgRNAs were used to develop PNT2 sgCIC1 and PNT2 sgCIC2 cells. Blasticidin (10 μg/ml) was used as a selection agent. PNT2shERFA1 +sgCIC1 and PNT2shERFA1 +sgCIC2 were developed from the combination of the above two shRNA and sgRNAs. All PNT2 cells were grown in DMEM media supplemented with 10% FBS, 100 IU/ml penicillin and 100 μ g/ml streptomycin.</p><p>DU-145 ERF, DU-145 CIC KO (sgCIC1, sgCIC2) and DU-145 ERF +CIC KO (ERF +sgCIC1, ERF +sgCIC2) were derived from parental DU-145 cell line. Lentiviral GFP-tagged ERF (GeneCopoeia, EX-S0501-Lv122) was used to develop DU-145 ERF cells with puromycin (1 μg/ml) as a selection marker. The above-mentioned two sgRNAs were used to develop DU-145 sgCIC1 and DU-145 sgCIC2 cells with blasticidin (15 μg/ml) as the selection agent. DU-145 ERF +sgCIC1 and DU-145 ERF +sgCIC2 were developed from the combination of the above two.</p><p>PC-3 ERF KD (shERFA1), PC-3 ERF OE, PC-3 CIC OE, PC-3 (ERF +CIC) OE cells were derived from parental PC-3 cell line. shRNAs targeting ERF (Sigma-Aldrich: TRCN000001391) and lentiviral GFP-tagged ERF (GeneCopoeia, EX-S0501-Lv122) were used to develop PC-3 shERFA1 and PC-3 ERF OE, respectively. PC-3 CIC OE cells were developed using CIC-Myc-tag plasmid purchased from Origene (CAT#: RC215209).</p><p>Geneticin (250 μg/ml) was used as a selection agent. PC-3 (ERF +CIC) OE cells were developed using a combination of ERF-GFP and CIC-Myc overexpressing plasmid.</p><p>All DU-145 and PC-3 cells were grown in RPMI 1640 media supplemented with 10% FBS, 100 I U/ml penicillin and 100 μ g/ml streptomycin, respectively. All cell lines were maintained at 37 °C in a humidified atmosphere at 5% CO2. All the above mentioned stable cell lines were validated by analyzing the expression of CIC and ERF using qPCR and western blot analysis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A-C, I</xref>).</p><p>BRD32048 is an ETV1 inhibitor that was purchased from Sigma-Aldrich (CAT#:SML1346).</p></sec><sec id="s4-2"><title>Analysis of PCa datasets from cBioPortal</title><p>15 PCa datasets (see <xref ref-type="fig" rid="fig1">Figure 1c</xref> for individual studies) were queried for alterations in CIC and ERF using the cBioPortal platform ‘query by gene’ function. Stratification into ‘ERF-CIC No co-deletion’ and ‘ERF-CIC co-deletion’ was performed in cBioPortal and associated with ‘Gleason Score’, ‘AJCC Primary Tumor T Stage’, and DFS and PFS using the ‘Plots’ and ‘Comparison/Survival’ functions. p-values for comparison between Gleason and Tumor Stage were calculated using FET and survival curves were calculated by Log-rank test.</p><p>For the CIC and ERF mutational analysis in primary prostate vs. metastatic castrate resistant PCa, we selected studies that purely represented primary prostate tumors (PNAS 2014, Cell 2014, Nature 2017) and advanced mCRPC (Nature 2012, Cell 2015, PNAS 2019).</p></sec><sec id="s4-3"><title>Colony formation assay</title><p>Equal number of cells from cell lines (500–600 cells/well) were seeded in a 6-well plate. Cells were allowed to form colonies for 7 days. At day 7, cells were fixed and stained with 0.5% crystal violet solution after washing with PBS and performed in triplicate.</p><p>Finally, the colonies with &gt;50 cells were counted under an imageJ software.</p></sec><sec id="s4-4"><title>Tumorsphere assay</title><p>Approximately 25,000 cells from different groups were cultured in tumorsphere media at 37 °C and 5% CO2 for 7 days. Tumorsphere medium contains serum free DMEM /F12 supplemented with 10 ng/ml FGF (fibroblast growth factor), 20 ng/ml EGF (epidermal growth factor), 1xITS (Insulin-Transferrin-Selenium) and B27 supplement. On day 7, images of different areas of the wells were taken using confocal. The size of the sphere was calculated using Fiji (ImageJ) software in all the tested groups. Each group consisted of three replicate wells and at least 6 images (n&gt;/=6).</p></sec><sec id="s4-5"><title>Subcutaneous tumor xenograft assays</title><p>Four week old male SCID mice were purchased from Jackson Laboratory. Mice were kept under specific pathogen-free conditions and facilities were approved by the UCSF IACUC. To prepare cell suspensions, PNT2 and its other genetic variants (PNT2 ERF KD, PNT2 CIC KO, PNT2 ERF KD +CIC KO) were briefly trypsinized, quenched with 10% FBS RPMI media and resuspended in PBS. Cells were pelleted again and mixed with PBS/Matrigel matrix (1:1) for a final concentration of 0.1×10<sup>5</sup> cells/µl. A 100 μl cell suspension containing 1×10<sup>6</sup> cells were injected (s.c.) in the right and left flanks of immunodeficient mice (n=10/group). Mice were observed for tumor formation in different groups over 7 weeks. For other subcutaneous xenografts, four week old male mice (NU/J) were purchased from Jackson Laboratory and were six-eight weeks old at time of experiment. 1.0×10<sup>6</sup> DU-145 cells and its variants (DU-145 ERF, DU-145 CICKO and DU-145 ERF +CICKO) were resuspended in PBS/Matrigel (1:1) matrix and injected s.c. into the right and left flanks of nude mice (n=10/group). Tumor volume was measured twice per week using Vernier caliper. Tumor volume was determined using caliper measurements of tumor length (L) and width (W) according to the formula V = (L X W2) X 0.52.</p><p>Similarly, 1.0×10<sup>6</sup> PC-3 tumor cells and its variants (PC-3 ERFOE, CICOE) were injected subcutaneously in flanks of male nude mice (NU/J), n=10/group and tumor volume was monitored in different groups. Mice body weight was measured in all the experiments throughout the study. At the end of the experiment, mice were sacrificed by CO2 overdose in accordance with IACUC guidelines.</p></sec><sec id="s4-6"><title>Viability assays</title><p>5000 cells were plated in a 12 well plate. Crystal violet staining was performed 5 days after cell plating with 3 replicates per group. CellTiter Glo experiments were performed according to the manufacturer’s protocol. In brief, cells were plated in a 96-well plate, and analyzed on a Spectramax microplate reader (Molecular Devices) at different days. Each assay was performed with six replicate wells.</p></sec><sec id="s4-7"><title>Transwell invasion assays</title><p>RPMI with 10% FBS was added to the bottom well of a trans-well chamber. 2.5×10^4 cells resuspended in serum free media was then added to the top 8 µm pore matrigel coated (invasion) or non-coated (migration) trans-well insert (BD Biosciences). After 20 hr, non-invading cells on the apical side of inserts were scraped off and the trans-well membrane was fixed in methanol for 15 min and stained with Crystal Violet for 30 min. The basolateral surface of the membrane was visualized with a Zeiss Axioplan II immunofluorescent microscope at 5×. Each trans-well insert was imaged in five distinct regions at 5×and performed in triplicate. % invasion was calculated by dividing the mean # of cells invading through Matrigel membrane / mean # of cells migrating through control insert.</p></sec><sec id="s4-8"><title>Wound healing assays</title><p>Cells were plated at a density of 0.5×10<sup>6</sup> cells/well and incubated to form a monolayer in 6-well dishes. Once a uniform monolayer was formed, wound was created by scratching the monolayer with a 1 ml sterile tip. Floating cells were removed by washing the cells with PBS three times. Images of the wound were taken at this point using bright field microscope and considered as a 0 hr time point. Furthermore, media was added in all the wells and cells were left to migrate either for 24 hr (DU-145 cells) or 48 hr (PNT2 ond PC-3 cells). At end point, wound was imaged again using bright field microscope. The wound area at different points was calculated using ImageJ software. Each group consisted of at least three replicate wells.</p></sec><sec id="s4-9"><title>DAVID functional clustering analysis</title><p>The 91 shared candidate target genes between CIC and ERF identified through our ChIPSeq analysis in PNT2 and VCaP cells, respectively, were used as an input list for analysis using the DAVID Bioinformatics Database (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov">https://david.ncifcrf.gov</ext-link>).</p></sec><sec id="s4-10"><title>Real-time quantitative PCR (RT-qPCR)</title><p>RT-qPCR was performed in PNT2, DU145 and PC3 cells. Isolation and purification of RNA was performed using RNeasy Mini Kit (Qiagen). 500 ng of total RNA was used in a reverse transcriptase reaction with the SuperScript III firststrand synthesis system (Invitrogen). Quantitative PCR included three replicates per cDNA sample. Human CIC (Cat#. Hs00943425_g1), ERF (Cat#. Hs01100070_g1), ETV1 (Cat#. Hs00951951_m1), ETV4 (Cat#. Hs00383361_g1), ETV5 (Cat#. Hs00927557_m1), and endogenous controls GAPDH (Cat#. Hs02758991_g1) were amplified with Taqman gene expression assay (Applied Biosystems). Expression data were acquired using an ABI Prism 7900HT Sequence Detection System (Thermo Fisher Scientific). Expression of each target was calculated using the 2−ΔΔCt method and expressed as relative mRNA expression.</p></sec><sec id="s4-11"><title>Chip-Seq and PCR</title><p>ChIP was performed on PNT2 and DU-145 cells with the SimpleChIP Enzymatic Chromatin IP kit, Cell Signaling Technology #9003 in accordance with the manufacturer’s protocol. The antibodies used for IP were as follows: CIC (Thermo Fisher Scientific – PA146018) and ERF (Thermo Fisher Scientific –PA530237). Paired-end 150 bp (PE150) sequencing on an Illumina HiSeq platform was then performed. ChIP-Seq peak calls were identified through Mode-based Analysis of ChIP-Seq (MACS). For ETV1 ChIP-PCR validation, primers were designed in the proximal regulatory element of ETV1. The promoter primer sequences are listed in supplementary experimental methods:</p><p>VCaP ERF ChIP-Seq was previously performed (<xref ref-type="bibr" rid="bib6">Bose et al., 2017</xref>) and publicly available in the GEO database: GSE83653. For this analysis, the samples used are listed in supplementary experimental methods.</p><p>Promoter primer sequences for ChIP-PCR and ChIP-Seq are provided in the Supplementary Methods (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p></sec><sec id="s4-12"><title>GSM2612455_INPUT red replicate two luciferase promoter assay</title><p>293T and DU-145 cells were split into a 96 well plate to achieve 50–70% confluence the day of transfection. LightSwitch luciferase assay system (SwitchGear Genomics) was used per the manufacturer’s protocol. Briefly, a mixture containing FuGENE 6 transfection reagent, 50 ng Luciferase GoClone ETV1 promoter (S720645) plasmid DNA, 50 ng of either control (empty) vector or fully sequenced ERF cDNA (GeneCopoeia [EX-S0501Lv122]), were added to each well. All transfections were performed in quintuplicate. The plates were assessed for luciferase activity after 48 hr of treatment.</p></sec><sec id="s4-13"><title>Single-sample gene set enrichment analysis (ssGSEA)</title><p>Gene-level expression of our dual CIC and ERF deficient PNT2 cells are computed using RSEM (<xref ref-type="bibr" rid="bib40">Setlur et al., 2008</xref>) (Version 1.3.3) and log-2 normalized. The signature gene set of dual <italic>CIC</italic> and <italic>ERF</italic> deficient PNT2 cells (<italic>ERF</italic> KD +<italic>CIC</italic> KO) is defined as the top upregulated genes compared to the CIC and ERF WT cells. The ssGSEA module on GenePattern was then used to project the TCGA-PRAD dataset onto the transcriptional space defined by both the <italic>ERF</italic> KD +<italic>CIC</italic> KO signature gene set and previously established gene sets including the <italic>ETV1</italic>-regulated gene set, <italic>ERF</italic> KD signature and <italic>TMPRSS2-ERG</italic> fusion signature. The ssGSEA enrichment scores of the <italic>ERF</italic> KD +<italic>CIC</italic> KO signature gene set for the TCGA-PRAD samples are compared with the scores of the other signature gene sets and visualized in heatmaps and used for downstream association analyses.</p></sec><sec id="s4-14"><title>Gene knockdown (KD) and OE assays</title><p>ON-TARGET plus Scramble, ETV1 (L-003801-00-0005) and CIC (L-015185-01-0005) siRNAs were obtained from GE Dharmacon and transfection was performed with Dharmafect transfection reagent per manufacturer recommendations. ETV1 inhibitorBRD32048 (SML1346) was purchased from Millipore Sigma. Lentiviral GFP-tagged ERF was obtained from GeneCopoeia (EX-S0501-Lv122). pCMV-CIC with myc-tag was purchased from Origene and validated previously.</p></sec><sec id="s4-15"><title>Experimental plan for experiments using ETV1 inhibitor</title><p>Cells were plated at a density of 0.2×10<sup>6</sup> in a 6-well plate. Next day, cells were transfected with siScramble and siCIC. After 48 hr, 25 μM and 50 μM of BMS32048 (ETV1 inhibitor) was added to both the transfected groups and control groups were treated with DMSO. 24 hr post ETV1 inhibitor treatment, cells from all the groups were replated for viability assay in a 24-well plate (n=3) and transwell invasion assay (n=3). Viability assay was performed using crystal violet. The relative density of crystal violet and % invasion was calculated comparing siCIC with siSCRM conditions in each respective drug concentration.</p></sec><sec id="s4-16"><title>Western blot analysis</title><p>Adherent cells were washed and lysed with RIPA buffer supplemented with proteinase and phosphatase inhibitors. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes and blotted with antibodies recognizing: CIC (Thermo Fisher Scientific –PA146018), ERF (Thermo Fisher Scientific –PA530237), ETV1 (Thermo Fisher Scientific –MA515461), HSP90 (Cell Signaling– 4874 S), Actin (Cell Signaling – 4970 S). All immunoblots represent at least two independent experiments.</p></sec><sec id="s4-17"><title>Co-immunoprecipitation assays</title><p>293T cells were transfected with GFP-tagged ERF for 48 hr, lysed, quantified, and incubated with either IgG (Cell Signaling Technology; 2729) fused to Dynabeads Protein G (Thermo Fisher Scientific; 10004D) or anti-GFP magnetic beads overnight at 4 °C. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with antibodies recognizing GFP or CIC. Myc-tagged CIC was transfected into HEK293T cells for 48 hr, lysed, quantified, and incubated with either IgG (Cell Signaling Technology; 2729) fused to Dynabeads Protein G (Thermo Fisher Scientific; 10004D) or anti-myc magnetic beads overnight at 4 °C. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with antibodies recognizing Myc or ERF.</p></sec><sec id="s4-18"><title>Statistical analysis</title><p>Experimental data are presented as mean +/-Standard Deviation (SD) or Standard Error of the Mean (SEM). P-values derived for all in-vitro experiments were calculated using two-tailed student’s t-test or one-way ANOVA. The detailed statistical analysis performed for each experiment is defined in the figure legends.</p></sec><sec id="s4-19"><title>Study approval</title><p>For tumor xenograft studies, specific pathogen-free conditions and facilities were approved by the American Association for Accreditation of Laboratory Animal Care. Surgical procedures were reviewed and approved by the UCSF Institutional Animal Care and Use Committee (IACUC), protocol #AN178670-03.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>For tumor xenograft studies, specific pathogen-free conditions and facilities were approved by the American Association for Accreditation of Laboratory Animal Care. Surgical procedures were reviewed and approved by the UCSF Institutional Animal Care and Use Committee (IACUC), protocol #AN178670-03.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of 91 CIC and ERF shared putative target genes used for DAVID analysis.</title></caption><media xlink:href="elife-77072-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Promoter primer sequences for ChIP-PCR and ChIP-Seq experiments.</title></caption><media xlink:href="elife-77072-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-77072-transrepform1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All sequencing data including RNASeq and ChIP seq have been deposited in GEO under accession codes GSE216732 and GSE216318, respectively.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Kriska Ponce</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Decoding the Protein Composition of Whole Nucleosomes with Nuc-MS</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE216732">GSE216732</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Kriska Ponce</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE216318">GSE216318</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Loss of Function Mutations in ETS2 Repressor Factor (ERF) Reveal a Balance Between Positive and Negative ETS Factors Controlling Prostate Oncogenesis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83653">GSE83653</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank members of the Okimoto and Huang labs and funding support from the following sources: A National Cancer Institute (NCI) Cancer Center Support Grant (P30CA082103) and Benioff Initiative for Prostate Cancer Research Awards (N.G and R.A.O), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF- 2020R1A6A3A03039483)(J.W.K) and NCI K08-CA222625 and R37CA255453 awards to R.A.O.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Cyrta</surname><given-names>J</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Prandi</surname><given-names>D</given-names></name><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>I</given-names></name><name><surname>Cieslik</surname><given-names>M</given-names></name><name><surname>Benelli</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Fedrizzi</surname><given-names>T</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Robinson</surname><given-names>BD</given-names></name><name><surname>De Sarkar</surname><given-names>N</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Tomlins</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Nava Rodrigues</surname><given-names>D</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Mateo</surname><given-names>J</given-names></name><name><surname>Bianchini</surname><given-names>D</given-names></name><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Carreira</surname><given-names>S</given-names></name><name><surname>Rescigno</surname><given-names>P</given-names></name><name><surname>Filipenko</surname><given-names>J</given-names></name><name><surname>Vinson</surname><given-names>J</given-names></name><name><surname>Montgomery</surname><given-names>RB</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Heath</surname><given-names>EI</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Taplin</surname><given-names>ME</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>deBono</surname><given-names>JS</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genomic correlates of clinical outcome in advanced prostate cancer</article-title><source>PNAS</source><volume>116</volume><fpage>11428</fpage><lpage>11436</lpage><pub-id pub-id-type="doi">10.1073/pnas.1902651116</pub-id><pub-id pub-id-type="pmid">31061129</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>ST</given-names></name><name><surname>Rogers</surname><given-names>AD</given-names></name><name><surname>Chen</surname><given-names>MJ</given-names></name><name><surname>Dixit</surname><given-names>R</given-names></name><name><surname>Adnani</surname><given-names>L</given-names></name><name><surname>Frankiw</surname><given-names>LS</given-names></name><name><surname>Lawn</surname><given-names>SO</given-names></name><name><surname>Blough</surname><given-names>MD</given-names></name><name><surname>Alshehri</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Robbins</surname><given-names>SM</given-names></name><name><surname>Cairncross</surname><given-names>JG</given-names></name><name><surname>Schuurmans</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Capicua regulates neural stem cell proliferation and lineage specification through control of ets factors</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2000</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09949-6</pub-id><pub-id pub-id-type="pmid">31043608</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajuria</surname><given-names>L</given-names></name><name><surname>Nieva</surname><given-names>C</given-names></name><name><surname>Winkler</surname><given-names>C</given-names></name><name><surname>Kuo</surname><given-names>D</given-names></name><name><surname>Samper</surname><given-names>N</given-names></name><name><surname>Andreu</surname><given-names>MJ</given-names></name><name><surname>Helman</surname><given-names>A</given-names></name><name><surname>González-Crespo</surname><given-names>S</given-names></name><name><surname>Paroush</surname><given-names>Z</given-names></name><name><surname>Courey</surname><given-names>AJ</given-names></name><name><surname>Jiménez</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Capicua DNA-binding sites are general response elements for RTK signaling in <italic>Drosophila</italic></article-title><source>Development</source><volume>138</volume><fpage>915</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1242/dev.057729</pub-id><pub-id pub-id-type="pmid">21270056</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baena</surname><given-names>E</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name><name><surname>Linn</surname><given-names>DE</given-names></name><name><surname>Glass</surname><given-names>K</given-names></name><name><surname>Hamblen</surname><given-names>MJ</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Godinho</surname><given-names>FJ</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>GC</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients</article-title><source>Genes &amp; Development</source><volume>27</volume><fpage>683</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1101/gad.211011.112</pub-id><pub-id pub-id-type="pmid">23512661</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettegowda</surname><given-names>C</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Sausen</surname><given-names>M</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Rodriguez</surname><given-names>FJ</given-names></name><name><surname>Cahill</surname><given-names>DP</given-names></name><name><surname>McLendon</surname><given-names>R</given-names></name><name><surname>Riggins</surname><given-names>G</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Oba-Shinjo</surname><given-names>SM</given-names></name><name><surname>Marie</surname><given-names>SKN</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Bigner</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mutations in CIC and FUBP1 contribute to human oligodendroglioma</article-title><source>Science</source><volume>333</volume><fpage>1453</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1126/science.1210557</pub-id><pub-id pub-id-type="pmid">21817013</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>R</given-names></name><name><surname>Karthaus</surname><given-names>WR</given-names></name><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Iaquinta</surname><given-names>PJ</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wongvipat</surname><given-names>J</given-names></name><name><surname>Wasmuth</surname><given-names>EV</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Sullivan</surname><given-names>PS</given-names></name><name><surname>Doran</surname><given-names>MG</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Patruno</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><collab>International SU2C/PCF Prostate Cancer Dream Team</collab></person-group><year iso-8601-date="2017">2017</year><article-title>ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis</article-title><source>Nature</source><volume>546</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nature22820</pub-id><pub-id pub-id-type="pmid">28614298</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunda</surname><given-names>S</given-names></name><name><surname>Heir</surname><given-names>P</given-names></name><name><surname>Metcalf</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>ASC</given-names></name><name><surname>Agnihotri</surname><given-names>S</given-names></name><name><surname>Pusch</surname><given-names>S</given-names></name><name><surname>Yasin</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Burrell</surname><given-names>K</given-names></name><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>O</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Alamsahebpour</surname><given-names>A</given-names></name><name><surname>Nejad</surname><given-names>R</given-names></name><name><surname>Choi</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Zadeh</surname><given-names>G</given-names></name><name><surname>Aldape</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CIC protein instability contributes to tumorigenesis in glioblastoma</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>661</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08087-9</pub-id><pub-id pub-id-type="pmid">30737375</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular taxonomy of primary prostate cancer</article-title><source>Cell</source><volume>163</volume><fpage>1011</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.025</pub-id><pub-id pub-id-type="pmid">26544944</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>N</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Yoe</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>GY</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Jeon</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>YM</given-names></name><name><surname>Roh</surname><given-names>TY</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MiR-93/mir-106b/mir-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression</article-title><source>Oncotarget</source><volume>6</volume><fpage>23533</fpage><lpage>23547</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4372</pub-id><pub-id pub-id-type="pmid">26124181</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>JP</given-names></name><name><surname>Cooper</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ETS gene fusions in prostate cancer</article-title><source>Nature Reviews. Urology</source><volume>6</volume><fpage>429</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2009.127</pub-id><pub-id pub-id-type="pmid">19657377</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dissanayake</surname><given-names>K</given-names></name><name><surname>Toth</surname><given-names>R</given-names></name><name><surname>Blakey</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>O</given-names></name><name><surname>Campbell</surname><given-names>DG</given-names></name><name><surname>Prescott</surname><given-names>AR</given-names></name><name><surname>MacKintosh</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ERK/p90(rsk)/14-3-3 signalling has an impact on expression of PEA3 ets transcription factors via the transcriptional repressor capicúa</article-title><source>The Biochemical Journal</source><volume>433</volume><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1042/BJ20101562</pub-id><pub-id pub-id-type="pmid">21087211</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Brenner</surname><given-names>JC</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular pathways: targeting ETS gene fusions in cancer</article-title><source>Clinical Cancer Research</source><volume>20</volume><fpage>4442</fpage><lpage>4448</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0275</pub-id><pub-id pub-id-type="pmid">24958807</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>M</given-names></name><name><surname>Sabelnykova</surname><given-names>VY</given-names></name><name><surname>Yamaguchi</surname><given-names>TN</given-names></name><name><surname>Heisler</surname><given-names>LE</given-names></name><name><surname>Livingstone</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>V</given-names></name><name><surname>Shiah</surname><given-names>Y-J</given-names></name><name><surname>Yousif</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Masella</surname><given-names>AP</given-names></name><name><surname>Fox</surname><given-names>NS</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Prokopec</surname><given-names>SD</given-names></name><name><surname>Berlin</surname><given-names>A</given-names></name><name><surname>Lalonde</surname><given-names>E</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Trudel</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Beck</surname><given-names>TA</given-names></name><name><surname>Meng</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>D’Costa</surname><given-names>A</given-names></name><name><surname>Denroche</surname><given-names>RE</given-names></name><name><surname>Kong</surname><given-names>H</given-names></name><name><surname>Espiritu</surname><given-names>SMG</given-names></name><name><surname>Chua</surname><given-names>MLK</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Chong</surname><given-names>T</given-names></name><name><surname>Sam</surname><given-names>M</given-names></name><name><surname>Johns</surname><given-names>J</given-names></name><name><surname>Timms</surname><given-names>L</given-names></name><name><surname>Buchner</surname><given-names>NB</given-names></name><name><surname>Orain</surname><given-names>M</given-names></name><name><surname>Picard</surname><given-names>V</given-names></name><name><surname>Hovington</surname><given-names>H</given-names></name><name><surname>Murison</surname><given-names>A</given-names></name><name><surname>Kron</surname><given-names>K</given-names></name><name><surname>Harding</surname><given-names>NJ</given-names></name><name><surname>P’ng</surname><given-names>C</given-names></name><name><surname>Houlahan</surname><given-names>KE</given-names></name><name><surname>Chu</surname><given-names>KC</given-names></name><name><surname>Lo</surname><given-names>B</given-names></name><name><surname>Nguyen</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>CH</given-names></name><name><surname>Sun</surname><given-names>RX</given-names></name><name><surname>de Borja</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>CI</given-names></name><name><surname>Hopkins</surname><given-names>JF</given-names></name><name><surname>Govind</surname><given-names>SK</given-names></name><name><surname>Fung</surname><given-names>C</given-names></name><name><surname>Waggott</surname><given-names>D</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Chan-Seng-Yue</surname><given-names>MA</given-names></name><name><surname>Jung</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Bergeron</surname><given-names>A</given-names></name><name><surname>Dal Pra</surname><given-names>A</given-names></name><name><surname>Lacombe</surname><given-names>L</given-names></name><name><surname>Collins</surname><given-names>CC</given-names></name><name><surname>Sahinalp</surname><given-names>C</given-names></name><name><surname>Lupien</surname><given-names>M</given-names></name><name><surname>Fleshner</surname><given-names>NE</given-names></name><name><surname>He</surname><given-names>HH</given-names></name><name><surname>Fradet</surname><given-names>Y</given-names></name><name><surname>Tetu</surname><given-names>B</given-names></name><name><surname>van der Kwast</surname><given-names>T</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Bristow</surname><given-names>RG</given-names></name><name><surname>Boutros</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomic hallmarks of localized, non-indolent prostate cancer</article-title><source>Nature</source><volume>541</volume><fpage>359</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/nature20788</pub-id><pub-id pub-id-type="pmid">28068672</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futran</surname><given-names>AS</given-names></name><name><surname>Kyin</surname><given-names>S</given-names></name><name><surname>Shvartsman</surname><given-names>SY</given-names></name><name><surname>Link</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mapping the binding interface of ERK and transcriptional repressor capicua using photocrosslinking</article-title><source>PNAS</source><volume>112</volume><fpage>8590</fpage><lpage>8595</lpage><pub-id pub-id-type="doi">10.1073/pnas.1501373112</pub-id><pub-id pub-id-type="pmid">26124095</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dresdner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pl1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Khan</surname><given-names>AP</given-names></name><name><surname>Quist</surname><given-names>MJ</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Brenner</surname><given-names>JC</given-names></name><name><surname>Asangani</surname><given-names>IA</given-names></name><name><surname>Ateeq</surname><given-names>B</given-names></name><name><surname>Chun</surname><given-names>SY</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Sam</surname><given-names>L</given-names></name><name><surname>Anstett</surname><given-names>M</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Palanisamy</surname><given-names>N</given-names></name><name><surname>Ryslik</surname><given-names>GA</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The mutational landscape of lethal castration-resistant prostate cancer</article-title><source>Nature</source><volume>487</volume><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1038/nature11125</pub-id><pub-id pub-id-type="pmid">22722839</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helgeson</surname><given-names>BE</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Laxman</surname><given-names>B</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Singla</surname><given-names>N</given-names></name><name><surname>Montie</surname><given-names>JE</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5352</pub-id><pub-id pub-id-type="pmid">18172298</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermans</surname><given-names>KG</given-names></name><name><surname>van der Korput</surname><given-names>HA</given-names></name><name><surname>van Marion</surname><given-names>R</given-names></name><name><surname>van de Wijngaart</surname><given-names>DJ</given-names></name><name><surname>Ziel-van der Made</surname><given-names>A</given-names></name><name><surname>Dits</surname><given-names>NF</given-names></name><name><surname>Boormans</surname><given-names>JL</given-names></name><name><surname>van der Kwast</surname><given-names>TH</given-names></name><name><surname>van Dekken</surname><given-names>H</given-names></name><name><surname>Bangma</surname><given-names>CH</given-names></name><name><surname>Korsten</surname><given-names>H</given-names></name><name><surname>Kraaij</surname><given-names>R</given-names></name><name><surname>Jenster</surname><given-names>G</given-names></name><name><surname>Trapman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>7541</fpage><lpage>7549</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5930</pub-id><pub-id pub-id-type="pmid">18794142</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Carver</surname><given-names>BS</given-names></name><name><surname>Chang</surname><given-names>MT</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Huberman</surname><given-names>K</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Assel</surname><given-names>M</given-names></name><name><surname>Murali</surname><given-names>R</given-names></name><name><surname>Vickers</surname><given-names>A</given-names></name><name><surname>Scardino</surname><given-names>PT</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Reuter</surname><given-names>V</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Copy number alteration burden predicts prostate cancer relapse</article-title><source>PNAS</source><volume>111</volume><fpage>11139</fpage><lpage>11144</lpage><pub-id pub-id-type="doi">10.1073/pnas.1411446111</pub-id><pub-id pub-id-type="pmid">25024180</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>C</given-names></name><name><surname>McCown</surname><given-names>C</given-names></name><name><surname>Ivanov</surname><given-names>DN</given-names></name><name><surname>Tsodikov</surname><given-names>OV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural insight into the DNA binding function of transcription factor ERF</article-title><source>Biochemistry</source><volume>47</volume><fpage>4499</fpage><lpage>4506</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.0c00774</pub-id><pub-id pub-id-type="pmid">33175491</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Garofalo</surname><given-names>A</given-names></name><name><surname>Oh</surname><given-names>C</given-names></name><name><surname>Baco</surname><given-names>M</given-names></name><name><surname>Amin-Mansour</surname><given-names>A</given-names></name><name><surname>Rabasha</surname><given-names>B</given-names></name><name><surname>Bahl</surname><given-names>S</given-names></name><name><surname>Mullane</surname><given-names>SA</given-names></name><name><surname>Robinson</surname><given-names>BD</given-names></name><name><surname>Aldubayan</surname><given-names>S</given-names></name><name><surname>Khani</surname><given-names>F</given-names></name><name><surname>Karir</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Chimene-Weiss</surname><given-names>J</given-names></name><name><surname>Hofree</surname><given-names>M</given-names></name><name><surname>Romanel</surname><given-names>A</given-names></name><name><surname>Osborne</surname><given-names>JR</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Azabdaftari</surname><given-names>G</given-names></name><name><surname>Woloszynska-Read</surname><given-names>A</given-names></name><name><surname>Sfanos</surname><given-names>K</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Mesirov</surname><given-names>J</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Powell</surname><given-names>IJ</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Exome sequencing of african-american prostate cancer reveals loss-of-function <italic>erf</italic> mutations</article-title><source>Cancer Discovery</source><volume>7</volume><fpage>973</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0960</pub-id><pub-id pub-id-type="pmid">28515055</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez</surname><given-names>G</given-names></name><name><surname>Shvartsman</surname><given-names>SY</given-names></name><name><surname>Paroush</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The capicua repressor--a general sensor of RTK signaling in development and disease</article-title><source>Journal of Cell Science</source><volume>125</volume><fpage>1383</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1242/jcs.092965</pub-id><pub-id pub-id-type="pmid">22526417</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura-Saito</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>Y</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Kawaguchi</surname><given-names>N</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Mukai</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>T</given-names></name><name><surname>Motoi</surname><given-names>T</given-names></name><name><surname>Fukayama</surname><given-names>M</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Takizawa</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fusion between CIC and DUX4 up-regulates PEA3 family genes in ewing-like sarcomas with t(4;19)(q35;q13) translocation</article-title><source>Human Molecular Genetics</source><volume>15</volume><fpage>2125</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl136</pub-id><pub-id pub-id-type="pmid">16717057</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keld</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>B</given-names></name><name><surname>Downey</surname><given-names>P</given-names></name><name><surname>Cummins</surname><given-names>R</given-names></name><name><surname>Gulmann</surname><given-names>C</given-names></name><name><surname>Ang</surname><given-names>YS</given-names></name><name><surname>Sharrocks</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma</article-title><source>British Journal of Cancer</source><volume>105</volume><fpage>124</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.187</pub-id><pub-id pub-id-type="pmid">21673681</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TD</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Lightfoot</surname><given-names>SA</given-names></name><name><surname>Grande</surname><given-names>JP</given-names></name><name><surname>Johnson</surname><given-names>AJ</given-names></name><name><surname>van Deursen</surname><given-names>JM</given-names></name><name><surname>Wren</surname><given-names>JD</given-names></name><name><surname>Janknecht</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>706</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1172/JCI78132</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Yoe</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>CJ</given-names></name><name><surname>Jeong</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis</article-title><source>Hepatology</source><volume>67</volume><fpage>2287</fpage><lpage>2301</lpage><pub-id pub-id-type="doi">10.1002/hep.29738</pub-id><pub-id pub-id-type="pmid">29251790</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Ponce</surname><given-names>RK</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Capicua in human cancer</article-title><source>Trends in Cancer</source><volume>7</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.08.010</pub-id><pub-id pub-id-type="pmid">32978089</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeBlanc</surname><given-names>VG</given-names></name><name><surname>Firme</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Yip</surname><given-names>S</given-names></name><name><surname>Chittaranjan</surname><given-names>S</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade</article-title><source>The Journal of Pathology</source><volume>242</volume><fpage>206</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1002/path.4894</pub-id><pub-id pub-id-type="pmid">28295365</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YK</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Ponce</surname><given-names>RK</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma</article-title><source>PNAS</source><volume>117</volume><fpage>20776</fpage><lpage>20784</lpage><pub-id pub-id-type="doi">10.1073/pnas.2009137117</pub-id><pub-id pub-id-type="pmid">32788348</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>WG</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Prostate cancer</article-title><source>The New England Journal of Medicine</source><volume>349</volume><fpage>366</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1056/NEJMra021562</pub-id><pub-id pub-id-type="pmid">12878745</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Janknecht</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors</article-title><source>Biochimica et Biophysica Acta</source><volume>1826</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2012.02.002</pub-id><pub-id pub-id-type="pmid">22425584</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Breitenbuecher</surname><given-names>F</given-names></name><name><surname>Olivas</surname><given-names>VR</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Gini</surname><given-names>B</given-names></name><name><surname>Hofree</surname><given-names>M</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Hrustanovic</surname><given-names>G</given-names></name><name><surname>Flanagan</surname><given-names>J</given-names></name><name><surname>Tulpule</surname><given-names>A</given-names></name><name><surname>Blakely</surname><given-names>CM</given-names></name><name><surname>Haringsma</surname><given-names>HJ</given-names></name><name><surname>Simmons</surname><given-names>AD</given-names></name><name><surname>Gowen</surname><given-names>K</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Bivona</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inactivation of capicua drives cancer metastasis</article-title><source>Nature Genetics</source><volume>49</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/ng.3728</pub-id><pub-id pub-id-type="pmid">27869830</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Nanjo</surname><given-names>S</given-names></name><name><surname>Olivas</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>YK</given-names></name><name><surname>Ponce</surname><given-names>RK</given-names></name><name><surname>Oyama</surname><given-names>R</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Bivona</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>3401</fpage><lpage>3406</lpage><pub-id pub-id-type="doi">10.1172/JCI126366</pub-id><pub-id pub-id-type="pmid">31329165</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pop</surname><given-names>MS</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Garvie</surname><given-names>CW</given-names></name><name><surname>Theurillat</surname><given-names>JP</given-names></name><name><surname>Hartman</surname><given-names>EC</given-names></name><name><surname>Lewis</surname><given-names>TA</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Culyba</surname><given-names>EK</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Daniels</surname><given-names>DS</given-names></name><name><surname>Pagliarini</surname><given-names>R</given-names></name><name><surname>Ronco</surname><given-names>L</given-names></name><name><surname>Koehler</surname><given-names>AN</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein</article-title><source>Molecular Cancer Therapeutics</source><volume>13</volume><fpage>1492</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0689</pub-id><pub-id pub-id-type="pmid">24737027</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Liefeld</surname><given-names>T</given-names></name><name><surname>Gould</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>J</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>GenePattern 2.0</article-title><source>Nature Genetics</source><volume>38</volume><fpage>500</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/ng0506-500</pub-id><pub-id pub-id-type="pmid">16642009</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Taplin</surname><given-names>ME</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Attard</surname><given-names>G</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name><name><surname>Vinson</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Rathkopf</surname><given-names>DE</given-names></name><name><surname>Morris</surname><given-names>MJ</given-names></name><name><surname>Solomon</surname><given-names>SB</given-names></name><name><surname>Durack</surname><given-names>JC</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Lis</surname><given-names>RT</given-names></name><name><surname>Bowden</surname><given-names>M</given-names></name><name><surname>Balk</surname><given-names>SP</given-names></name><name><surname>Gaviola</surname><given-names>G</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Mostaghel</surname><given-names>EA</given-names></name><name><surname>Cheng</surname><given-names>HH</given-names></name><name><surname>Mulcahy</surname><given-names>H</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Plymate</surname><given-names>SR</given-names></name><name><surname>Dvinge</surname><given-names>H</given-names></name><name><surname>Ferraldeschi</surname><given-names>R</given-names></name><name><surname>Flohr</surname><given-names>P</given-names></name><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Zafeiriou</surname><given-names>Z</given-names></name><name><surname>Tunariu</surname><given-names>N</given-names></name><name><surname>Mateo</surname><given-names>J</given-names></name><name><surname>Perez-Lopez</surname><given-names>R</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Robinson</surname><given-names>BD</given-names></name><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name><name><surname>Tagawa</surname><given-names>ST</given-names></name><name><surname>Sigaras</surname><given-names>A</given-names></name><name><surname>Eng</surname><given-names>KW</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Heath</surname><given-names>EI</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Kantoff</surname><given-names>P</given-names></name><name><surname>de Bono</surname><given-names>JS</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrative clinical genomics of advanced prostate cancer</article-title><source>Cell</source><volume>161</volume><fpage>1215</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.001</pub-id><pub-id pub-id-type="pmid">26000489</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seim</surname><given-names>I</given-names></name><name><surname>Jeffery</surname><given-names>PL</given-names></name><name><surname>Thomas</surname><given-names>PB</given-names></name><name><surname>Nelson</surname><given-names>CC</given-names></name><name><surname>Chopin</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Whole-genome sequence of the metastatic PC3 and lncap human prostate cancer cell lines</article-title><source>G3: Genes, Genomes, Genetics</source><volume>7</volume><fpage>1731</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1534/g3.117.039909</pub-id><pub-id pub-id-type="pmid">28413162</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setlur</surname><given-names>SR</given-names></name><name><surname>Mertz</surname><given-names>KD</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Lupien</surname><given-names>M</given-names></name><name><surname>Perner</surname><given-names>S</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Pawitan</surname><given-names>Y</given-names></name><name><surname>Andrén</surname><given-names>O</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Adami</surname><given-names>HO</given-names></name><name><surname>Calza</surname><given-names>S</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name><name><surname>Tomlins</surname><given-names>S</given-names></name><name><surname>Fall</surname><given-names>K</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Andersson</surname><given-names>SO</given-names></name><name><surname>Varenhorst</surname><given-names>E</given-names></name><name><surname>Johansson</surname><given-names>JE</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer</article-title><source>Journal of the National Cancer Institute</source><volume>100</volume><fpage>815</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1093/jnci/djn150</pub-id><pub-id pub-id-type="pmid">18505969</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Hao</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Baseler</surname><given-names>MW</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Imamichi</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)</article-title><source>Nucleic Acids Res</source><volume>50</volume><fpage>W216</fpage><lpage>W221</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac194</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simón-Carrasco</surname><given-names>L</given-names></name><name><surname>Graña</surname><given-names>O</given-names></name><name><surname>Salmón</surname><given-names>M</given-names></name><name><surname>Jacob</surname><given-names>HKC</given-names></name><name><surname>Gutierrez</surname><given-names>A</given-names></name><name><surname>Jiménez</surname><given-names>G</given-names></name><name><surname>Drosten</surname><given-names>M</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inactivation of capicua in adult mice causes T-cell lymphoblastic lymphoma</article-title><source>Genes &amp; Development</source><volume>31</volume><fpage>1456</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1101/gad.300244.117</pub-id><pub-id pub-id-type="pmid">28827401</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simón-Carrasco</surname><given-names>L</given-names></name><name><surname>Jiménez</surname><given-names>G</given-names></name><name><surname>Barbacid</surname><given-names>M</given-names></name><name><surname>Drosten</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The capicua tumor suppressor: a gatekeeper of ras signaling in development and cancer</article-title><source>Cell Cycle</source><volume>17</volume><fpage>702</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1080/15384101.2018.1450029</pub-id><pub-id pub-id-type="pmid">29578365</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sizemore</surname><given-names>GM</given-names></name><name><surname>Pitarresi</surname><given-names>JR</given-names></name><name><surname>Balakrishnan</surname><given-names>S</given-names></name><name><surname>Ostrowski</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The ETS family of oncogenic transcription factors in solid tumours</article-title><source>Nature Reviews. Cancer</source><volume>17</volume><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.20</pub-id><pub-id pub-id-type="pmid">28450705</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Perner</surname><given-names>S</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>XW</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Tchinda</surname><given-names>J</given-names></name><name><surname>Kuefer</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Montie</surname><given-names>JE</given-names></name><name><surname>Shah</surname><given-names>RB</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer</article-title><source>Science</source><volume>310</volume><fpage>644</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1126/science.1117679</pub-id><pub-id pub-id-type="pmid">16254181</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Smith</surname><given-names>LR</given-names></name><name><surname>Roulston</surname><given-names>D</given-names></name><name><surname>Helgeson</surname><given-names>BE</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>JT</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Shah</surname><given-names>RB</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TMPRSS2:etv4 gene fusions define a third molecular subtype of prostate cancer</article-title><source>Cancer Research</source><volume>66</volume><fpage>3396</fpage><lpage>3400</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0168</pub-id><pub-id pub-id-type="pmid">16585160</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Lounsbury</surname><given-names>K</given-names></name><name><surname>Lum</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>LeBlanc</surname><given-names>V</given-names></name><name><surname>Chittaranjan</surname><given-names>S</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>Yip</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer</article-title><source>Oncogene</source><volume>38</volume><fpage>273</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0427-5</pub-id><pub-id pub-id-type="pmid">30093628</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>LH</given-names></name><name><surname>Hansen</surname><given-names>LJ</given-names></name><name><surname>Carpenter</surname><given-names>AB</given-names></name><name><surname>Moure</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Pirozzi</surname><given-names>CJ</given-names></name><name><surname>Diplas</surname><given-names>BH</given-names></name><name><surname>Waitkus</surname><given-names>MS</given-names></name><name><surname>Greer</surname><given-names>PK</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>McLendon</surname><given-names>RE</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>cic</italic> loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation</article-title><source>Cancer Research</source><volume>77</volume><fpage>6097</fpage><lpage>6108</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1018</pub-id><pub-id pub-id-type="pmid">28939681</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshiya</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>S</given-names></name><name><surname>Yoshizumi</surname><given-names>T</given-names></name><name><surname>Yugawa</surname><given-names>K</given-names></name><name><surname>Kurihara</surname><given-names>T</given-names></name><name><surname>Toshima</surname><given-names>T</given-names></name><name><surname>Harada</surname><given-names>N</given-names></name><name><surname>Hashisako</surname><given-names>M</given-names></name><name><surname>Yonemasu</surname><given-names>H</given-names></name><name><surname>Fukuzawa</surname><given-names>K</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of capicua on pancreatic cancer progression</article-title><source>Annals of Surgical Oncology</source><volume>28</volume><fpage>3198</fpage><lpage>3207</lpage><pub-id pub-id-type="doi">10.1245/s10434-020-09339-z</pub-id><pub-id pub-id-type="pmid">33216264</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77072.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.01.26.477820" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.26.477820"/></front-stub><body><p>This study provides insight into a potentially new genetically defined subset of prostate tumors driven by concurrent loss of the ERF and CIC tumor suppressor genes, in the absence of the canonical fusion event involving TMPRSS2 (around 10% of all cases). The work both validates previous findings and provides new data that support a compelling overall conclusion that combined ERF and CIC loss promotes prostate tumorigenesis by increasing expression of the oncogenic driver ETV1. This is an important study based on convincing evidence, that will be of interest to researchers in the field of prostate cancer.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77072.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Yip</surname><given-names>Stephen</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03sfybe47</institution-id><institution>BC Cancer Agency</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.26.477820">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.01.26.477820v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Erica Golemis as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Stephen Yip (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Can the authors confirm that the 15 cBioPortal datasets are really independent? To clarify this, it would be informative to have the numbers presented for each dataset in the associated Figure 1c legend. For example, the reader should then be able to see that the TCGA 2018 and TCGA numbers are quite small as most of these cases are also in TCGA 2015. Figure 1c is also hard to interpret given the data has been sorted (we assume) by CIC and ERF alterations. It would be more informative for the reader if it was sorted according to the study so we can see the distribution of alterations across each study. This then ties in with the later analysis looking at the difference in alterations between primary and metastatic prostate cancer datasets. It is also hard to interpret the stage data presented in Figure 1d, is it possible to condense the stages somehow? For example, condense T2A, T2B and T2C into one category (T2), etc.</p><p>2. Can the numbers of cases present in the primary and metastatic prostate cancer groups be specified in the text or in Figure 1e. Similarly, Can the number of cases present in each group of the survival analyses be specified in the text or in Figure 1g? Without any of the numbers requested above, it is difficult to determine the statistical power these analyses have.</p><p>3. The sample size used in each of the cell line assays should also be presented in the corresponding figure legends as (n=x). This includes bioreps of the cell culture experiments.</p><p>4. Supplementary Table 1 is missing.</p><p>5. The description of the ssGSEA work is very unclear both in the methods and Results sections. GSEA also stands for Gene Set Enrichment Analysis, not Gene Expression Analysis as stated in the results. It is unclear whether the authors used gene expression data from PNT2 cells or if they used data from the TCGA-PRAD dataset. If they used PNT2 gene expression data, how was this generated and how exactly was the TCGA-PRAD dataset involved? A more comprehensive and coherent description of these analyses is required in both the methods and Results sections. This includes the figure legend (4m) where there is no explanation for the abbreviations used.</p><p>6. The figures associated with the results describing the assessment of the ETV1 inhibitor in DU-145 cells actually show LNCap cells (Figure 4A-c). Please clarify.</p><p>7. The authors say they observe enhanced sensitivity to BRD32048 in DU-145 CIC KO cells, but this is not significant and should be noted. Why wasn't this work repeated in the other cell lines (PNT2 and PC-3, especially, given their contexts in prostate cancer metastatic potential) or in vivo? Or why not reconstitute ERF in DU-145 to see the effect of the inhibitor on CIC KO/KD alone? These experiments are essential to strengthen and generalize conclusions.</p><p>8. The supplementary figure (4d-f) also shows results from PC-3 cells, but this is not mentioned in the text.</p><p>9. The sub-figures (5b-5d) are in the wrong order, 5b shows invasiveness while 5c shows viability.</p><p>10. The methods section provides no information as to how the authors conducted their cell culture experiments using the ETV1 inhibitor (including technical/bioreps etc.), and as such, are not reproducible. Overall, the methods section is very disjointed and the methodology should be presented in the order that it is described in the results (aside from the cell line/culture information). This would also allow the authors to get rid of some repetition that is currently present and ensure there is still no missing methodology. In addition to some of the more specific methodology suggestions mentioned previously, can more information regarding the DAVID functional clustering analysis be added, including a reference/web link if available?</p><p>11. The authors should perform additional replicates to provide statistical significance for experiments currently lacking significance or temper their claims. For example, Figure 4l should probably be removed, unless additional replicates improve the data.</p><p>12. If ERF and CIC co-deletion function by increasing ETV1 transcription, then an increase in ETV1 mRNA levels in these tumors should be apparent in patient tumor datasets, such as those analyzed in Figure 1. This is a key missing analysis. This needs to be supplied.</p><p>13. A growth curve to measure proliferation rate changes after CIC and ERF manipulation would provide more rigor. Does ERF overexpression inhibit phenotypes in PNT2 cells?</p><p>14. Testing a few negative control genomic regions and showing no enrichment would alleviate the concern regarding controls for ChIP-PCR.</p><p>15. This phrase in the introduction needs references: &quot;…and inactivation of CIC de-represses ETV1, ETV4, and ETV5 transcription to promote tumor progression.&quot;</p><p>16. It is important to investigate potential proteomic interactions between CIC and ERF using Western blot and immunoprecipitation. Whether they bind to one another and what happens when only CIC or ERF is not expressed. What happens to the level of CIC, or ERF, in the absence of the other protein and the consequence of this, if there is altered expression.</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Erica Golemis (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>In general, no further experiments are needed, and the remaining critiques can be addressed by writing changes. Reviewer 3 is satisfied with the current version of the article, and Reviewer 1 has points that are largely directed at clarity; please address these. However, Reviewer 2 has residual issues with the significance and interpretation of the data. Please address point 1 in the discussion; for point 2, we suggest you present alternative analyses of the data (perhaps in a new supplemental figure) that allow the comparisons suggested, and discuss the significance of the results obtained through this analysis.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors have addressed the majority of my concerns, however, I don't feel I can comment on whether they have adequately addressed the other reviewers' comments. I have just a few points below that require the authors' attention.</p><p>1. As suggested, the authors have included a Table (Supplementary Table 1) that presents the CIC-ERF data for the various studies. However, I'm not sure the authors understood our comment regarding study overlap. For example, they present two rows of data for TCGA samples (PanCancer Atlas and Firehose Legacy) but these studies essentially consist of the same samples (the second just has a few more samples included). Thus, it is somewhat misleading to present two primary predominant cohorts with lower CIC-ERF alterations, when this is really just a single cohort. The authors also need to determine how many samples overlap the two SU2C/PCF studies and the MSK studies. This also applies to the data presented in Supplementary Figure 1 and impacts the statement in the Results section that says &quot;We analyzed over 6047 PCa tumors from 5839 patients&quot; (line 99), as this is not the case given numbers overlap across the studies.</p><p>Figure 1C still appears to be sorted by something other than study. If it was sorted by study, the top bar in this figure would have, for example, all the MSK-IMPACT prostate samples grouped together, all the PRAD (MSKCC, 2020) samples grouped together, etc. So there would be a solid teal block, a solid pink block, etc. At the moment you can see that on the far left of the &quot;Study&quot; bar, it starts with a mix of green and purple study samples, and so on.</p><p>2. The first and second sentences of the abstract now essentially say the same thing. The second sentence can be removed.</p><p>3. Ensure all gene names are italicised.</p><p>4. There is an issue with one of the references (TCGA 2015 publication).</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Overall the revision has not alleviated my concerns regarding the viability of the overall thesis that ERG and CIC co-deletion leading to activation of ETV1 is a driver of prostate cancer progression. There are two main reasons for this. First is the finding that there is no statistically significant difference in ETV1 expression between patient tumors with wild-type ERF and CIC, and co-deleted ERF and CIC. This seems to be a major problem. Second much of the critical data is underwhelming, does not reach statistical significance, and seems to be presented in ways intended to obscure the real results. Examples of this include the setting of every odd column to 1 and normalization of each even column to the prior odd column in Figures 5A, 5B, 5C, and 5S2B, C, E, and F – with no explanation that this is being done. This is also true of the ChIP control presented in the rebuttal, which includes an irrelevant input column that obscures the necessary comparison of IgG to anti-CIC and anti-ERF. It is also a problem that this control is presented in an entirely different way than the ChIP in Figure 4 that it is necessary to control for, and the control does not appear to be included in the revised manuscript.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>I am satisfied with the authors' responses and the additional experiments performed. I am somewhat disappointed that the selective knockdown of CIC and ERF did not further elucidate the functional interactions between these two proteins but I appreciate the effort and the underlying complexity of the interactions which could also be affected by cell and developmental contexts.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77072.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Can the authors confirm that the 15 cBioPortal datasets are really independent? To clarify this, it would be informative to have the numbers presented for each dataset in the associated Figure 1c legend. For example, the reader should then be able to see that the TCGA 2018 and TCGA numbers are quite small as most of these cases are also in TCGA 2015. Figure 1c is also hard to interpret given the data has been sorted (we assume) by CIC and ERF alterations. It would be more informative for the reader if it was sorted according to the study so we can see the distribution of alterations across each study. This then ties in with the later analysis looking at the difference in alterations between primary and metastatic prostate cancer datasets. It is also hard to interpret the stage data presented in Figure 1d, is it possible to condense the stages somehow? For example, condense T2A, T2B and T2C into one category (T2), etc.</p></disp-quote><p>We agree with the reviewer and provide a detailed table with (1) the total number of cases in each study; (2) the type of CIC and ERF deletion (shallow or deep); and (3) the percentage of cases in each study with a CIC-ERF co-deletion. This analysis further suggests that the CIC-ERF co-deletion is enriched in studies that were predominantly composed of advanced prostate cancers (highlighted in yellow) compared to studies predominantly composed of primary prostate cancer (highlighted in green). We have included this table as Figure 1 – Table Supplement 1.</p><p>In order to illustrate the frequency of CIC-ERF co-deletions in each study we sorted according to the study as recommended by the reviewer. These data indicate that CIC-ERF co-deletions are observed at a higher frequency in studies that predominantly analyzed advanced prostate cancer relative to primary prostate cancers. We have incorporated this figure into our revised manuscript as Figure 1 – Supplementary Figure 1.</p><p>With respect to the staging data, we utilized the presorted selection in cBioPortal and were unfortunately, unable to further condense the sub-stages into a single staging category (ie. T2A, T2B, T2C into T2).</p><disp-quote content-type="editor-comment"><p>2. Can the numbers of cases present in the primary and metastatic prostate cancer groups be specified in the text or in Figure 1e.</p></disp-quote><p>We agree with the reviewer and have now incorporated detailed information on the number of cases in each of the primary and metastatic prostate cancer groups. We provide this information below and have incorporated these numbers into the text.</p><p>Primary prostate cancer cohorts:</p><p>PNAS 2014. Hieronymus et al.</p><p>272 primary prostate cancers</p><p>Cell 2015. TCGA</p><p>333 primary prostate cancers</p><p>Nature 2017. Fraser et al.</p><p>477 primary (localized, non-indolent) prostate cancer.</p><p>Metastatic prostate cancer cohorts:</p><p>Nature 2012. Grasso et al.</p><p>50 metastatic CRPCs and 11 treatment-naive, high-grade localized prostate cancers.</p><p>Cell 2015. Robinson et al.</p><p>150 mCRPC</p><p>PNAS 2019. Abida et al.</p><p>429 mCRPC</p><disp-quote content-type="editor-comment"><p>Similarly, Can the number of cases present in each group of the survival analyses be specified in the text or in Figure 1g? Without any of the numbers requested above, it is difficult to determine the statistical power these analyses have.</p></disp-quote><p>Again, we agree that adding these numbers are informative and have incorporated them into the text.</p><p>Disease-free survival (DFS):</p><p>Altered: 90 (# of total) 25 (# of events)</p><p>Non-altered 910 (# of total) 153 (# of events)</p><p>Progression-free survival (PFS):</p><p>Altered: 52 (# of total) 16 (# of events)</p><p>Non-altered: 442 (# of total) 77(# of events)</p><disp-quote content-type="editor-comment"><p>3. The sample size used in each of the cell line assays should also be presented in the corresponding figure legends as (n=x). This includes bioreps of the cell culture experiments.</p></disp-quote><p>We have now incorporated the sample size for each experiment in the corresponding figure legends.</p><disp-quote content-type="editor-comment"><p>4. Supplementary Table 1 is missing.</p></disp-quote><p>We apologize for this oversight and have now incorporated this table as Supplemental Table 2 in the revised version of our manuscript.</p><disp-quote content-type="editor-comment"><p>5. The description of the ssGSEA work is very unclear both in the methods and Results sections. GSEA also stands for Gene Set Enrichment Analysis, not Gene Expression Analysis as stated in the results. It is unclear whether the authors used gene expression data from PNT2 cells or if they used data from the TCGA-PRAD dataset. If they used PNT2 gene expression data, how was this generated and how exactly was the TCGA-PRAD dataset involved? A more comprehensive and coherent description of these analyses is required in both the methods and Results sections. This includes the figure legend (4m) where there is no explanation for the abbreviations used.</p></disp-quote><p>We agree with the Reviewer and have expanded the methods and Results sections to include additional details on how we performed the ssGSEA. We also apologize for the oversight, we have changed Gene Expression Analysis to Gene Set Enrichment Analysis.</p><disp-quote content-type="editor-comment"><p>6. The figures associated with the results describing the assessment of the ETV1 inhibitor in DU-145 cells actually show LNCap cells (Figure 4A-c). Please clarify.</p></disp-quote><p>We have added the explanation describing LNCaP cells for supplementary figure (4a-c)</p><disp-quote content-type="editor-comment"><p>7. The authors say they observe enhanced sensitivity to BRD32048 in DU-145 CIC KO cells, but this is not significant and should be noted. Why wasn't this work repeated in the other cell lines (PNT2 and PC-3, especially, given their contexts in prostate cancer metastatic potential) or in vivo? Or why not reconstitute ERF in DU-145 to see the effect of the inhibitor on CIC KO/KD alone? These experiments are essential to strengthen and generalize conclusions.</p></disp-quote><p>We thank the reviewer for this comment. We have now performed additional studies to address this concern. In particular, we genetically silenced <italic>CIC</italic> and <italic>ERF</italic> in PNT2 cells and observed enhanced sensitivity to the ETV1 inhibitor. Consistent with these results we also knocked down <italic>ERF</italic> in <italic>CIC</italic> deficient PC-3 cells and again noted an increase in ETV1 inhibitor sensitivity compared to scramble control. These data are incorporated into the revised manuscript as Figure 5 —figure supplement 1A-F.</p><p>Finally, we reconstituted ERF into ERF deficient DU145 cells with CIC KO. We did not observe a significant difference in ETV1 inhibitor sensitivity in this setting.</p><disp-quote content-type="editor-comment"><p>8. The supplementary figure (4d-f) also shows results from PC-3 cells, but this is not mentioned in the text.</p></disp-quote><p>We apologize for this oversight and have now mentioned PC-3 cells in the text.</p><disp-quote content-type="editor-comment"><p>9. The sub-figures (5b-5d) are in the wrong order, 5b shows invasiveness while 5c shows viability.</p></disp-quote><p>We apologize for this error. We have corrected the order of the sub-figure.</p><disp-quote content-type="editor-comment"><p>10. The methods section provides no information as to how the authors conducted their cell culture experiments using the ETV1 inhibitor (including technical/bioreps etc.), and as such, are not reproducible. Overall, the methods section is very disjointed and the methodology should be presented in the order that it is described in the results (aside from the cell line/culture information). This would also allow the authors to get rid of some repetition that is currently present and ensure there is still no missing methodology. In addition to some of the more specific methodology suggestions mentioned previously, can more information regarding the DAVID functional clustering analysis be added, including a reference/web link if available?</p></disp-quote><p>We have added a paragraph in the methods section describing the methodology using the ETV1 inhibitor. Overall, we have also restructured the methods section and the methodology is presented in the order as they appear in the Results section. We have also included a web link and references to DAVID in the manuscript text and methods sections.</p><disp-quote content-type="editor-comment"><p>11. The authors should perform additional replicates to provide statistical significance for experiments currently lacking significance or temper their claims. For example, Figure 4l should probably be removed, unless additional replicates improve the data.</p></disp-quote><p>We completely agree with the reviewer. We have removed figure 4l from the manuscript.</p><disp-quote content-type="editor-comment"><p>12. If ERF and CIC co-deletion function by increasing ETV1 transcription, then an increase in ETV1 mRNA levels in these tumors should be apparent in patient tumor datasets, such as those analyzed in Figure 1. This is a key missing analysis. This needs to be supplied.</p></disp-quote><p>We used the largest prostate cancer dataset (n=455) and observed a trend but not a statistically significant difference in ETV1 expression in tumors that harbored the CIC-ERF co-deletion compared to CIC-ERF replete tumors.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>13. A growth curve to measure proliferation rate changes after CIC and ERF manipulation would provide more rigor. Does ERF overexpression inhibit phenotypes in PNT2 cells?</p></disp-quote><p>We assessed the growth rate (over 7 days) of PNT2 cells engineered to express <italic>shERF</italic>, <italic>sgCIC</italic> or combinatorial silencing of ERF (<italic>shERF</italic>) and CIC (<italic>sgCIC</italic>). We observed an increase in growth rate in PNT2 cells with dual ERF and CIC suppression compared to PNT2 control and either <italic>shERF</italic> or <italic>sgCIC</italic> alone.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-sa2-fig2-v1.tif"/></fig><p>We overexpressed ERF in PNT2 cells but did not observe a significant difference in viability (crystal violet or cell-titer glo assays) or in colony formation.</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-sa2-fig3-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>14. Testing a few negative control genomic regions and showing no enrichment would alleviate the concern regarding controls for ChIP-PCR.</p></disp-quote><p>We used two commercially validated human negative control q-pcr primer sets from Active Motif as an additional layer of control to address this concern. Using these primers targeting Gene Deserts on chromosome 12 and 4, we made comparisons to either IgG control or Input (2%).</p><fig id="sa2fig4" position="float"><label>Author response image 4.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-sa2-fig4-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>15. This phrase in the introduction needs references: &quot;…and inactivation of CIC de-represses ETV1, ETV4, and ETV5 transcription to promote tumor progression.&quot;</p></disp-quote><p>We have added the references for the indicated phrase.</p><disp-quote content-type="editor-comment"><p>16. It is important to investigate potential proteomic interactions between CIC and ERF using Western blot and immunoprecipitation. Whether they bind to one another and what happens when only CIC or ERF is not expressed. What happens to the level of CIC, or ERF, in the absence of the other protein and the consequence of this, if there is altered expression.</p></disp-quote><p>We agree with the reviewer and have performed co-immunoprecipitation experiments to address these concerns. Specifically, using HEK293T cells we expressed and pulled down GFP-tagged ERF, probing for CIC by western blot. CIC did not co-immunoprecipitate with GFP-tagged ERF under these conditions. The reciprocal experiment was also performed through expression of Myc-tagged CIC in HEK293T cells. ERF did not co-immunoprecipitate with CIC under these conditions. These data indicate that CIC and ERF do not interact in HEK293T cells. These studies have been incorporated to the revised manuscript as Figure 4 —figure supplement 1K-L.</p><p>We next performed ERF knockdown (KD) and ERF overexpression (OE) studies in HEK293T cells as requested by the Reviewer. Interestingly, we observed an increase in CIC expression following either ERF KD or ERF OE.</p><fig id="sa2fig5" position="float"><label>Author response image 5.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-sa2-fig5-v1.tif"/></fig><p>Moreover, we assessed ERF expression following CIC knockout or CIC overexpression in 293T cells. CIC expression increased using a single crispr-based sgRNA (sgCIC1) but this finding was not consistently observed with sgCIC2. CIC overexpression also increased ERF expression compared to control. Collectively, these findings indicate that the functional relationship between CIC and ERF may be complex and warrants further investigation into how these two proteins regulate one another. This will be an area of future interest and investigation.</p><fig id="sa2fig6" position="float"><label>Author response image 6.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77072-sa2-fig6-v1.tif"/></fig><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The authors have addressed the majority of my concerns, however, I don't feel I can comment on whether they have adequately addressed the other reviewers' comments. I have just a few points below that require the authors' attention.</p><p>1. As suggested, the authors have included a Table (Supplementary Table 1) that presents the CIC-ERF data for the various studies. However, I'm not sure the authors understood our comment regarding study overlap. For example, they present two rows of data for TCGA samples (PanCancer Atlas and Firehose Legacy) but these studies essentially consist of the same samples (the second just has a few more samples included). Thus, it is somewhat misleading to present two primary predominant cohorts with lower CIC-ERF alterations, when this is really just a single cohort. The authors also need to determine how many samples overlap the two SU2C/PCF studies and the MSK studies. This also applies to the data presented in Supplementary Figure 1 and impacts the statement in the Results section that says &quot;We analyzed over 6047 PCa tumors from 5839 patients&quot; (line 99), as this is not the case given numbers overlap across the studies.</p></disp-quote><p>We agree with the reviewer. We have removed the statement “we analyzed over 6047 PCa tumors from 5839 patients”.</p><p>We also incorporated the following statement within the text to hopefully bring additional clarity. “One limitation of this analysis is that individual studies included overlapping tumors from the same patient (ie. TCGA PanCancer and Firehose Legacy cohorts).” Moreover, we emphasized in the text that we used this correlative analysis to generate a hypothesis to explore the functional interaction between CIC and ERF in the context of prostate cancer progression.</p><disp-quote content-type="editor-comment"><p>Figure 1C still appears to be sorted by something other than study. If it was sorted by study, the top bar in this figure would have, for example, all the MSK-IMPACT prostate samples grouped together, all the PRAD (MSKCC, 2020) samples grouped together, etc. So there would be a solid teal block, a solid pink block, etc. At the moment you can see that on the far left of the &quot;Study&quot; bar, it starts with a mix of green and purple study samples, and so on.</p></disp-quote><p>Figure 1C was sorted by gene alteration. For this analysis, we sorted by <italic>CIC</italic> and aligned this with <italic>ERF</italic> alterations. In response to the Reviewer, we previously incorporated the frequency of CIC and ERF co-deletions found in each cohort/study in Figure 1 – Supplementary Figure 1.</p><disp-quote content-type="editor-comment"><p>2. The first and second sentences of the abstract now essentially say the same thing. The second sentence can be removed.</p></disp-quote><p>We agree with the Reviewer and have removed the first sentence of the Abstract.</p><disp-quote content-type="editor-comment"><p>3. Ensure all gene names are italicised.</p></disp-quote><p>We have reviewed the manuscript and italicized all gene names.</p><disp-quote content-type="editor-comment"><p>4. There is an issue with one of the references (TCGA 2015 publication).</p></disp-quote><p>We thank the reviewer for identifying this issue. We have corrected the reference.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Overall the revision has not alleviated my concerns regarding the viability of the overall thesis that ERG and CIC co-deletion leading to activation of ETV1 is a driver of prostate cancer progression. There are two main reasons for this. First is the finding that there is no statistically significant difference in ETV1 expression between patient tumors with wild-type ERF and CIC, and co-deleted ERF and CIC. This seems to be a major problem.</p></disp-quote><p>We have expanded the Discussion section to include a paragraph on these findings.</p><p>“A limitation of this targeted approach in prostate cancer patients is that we did not find a statistically significant difference in <italic>ETV1</italic> transcript levels in <italic>CIC-ERF</italic> co-deleted tumors compared to <italic>CIC-ERF</italic> replete tumors in the TCGA-PRAD (n=455) dataset. One potential explanation is that ETV1 is commonly upregulated in human prostate cancers through mechanisms beyond CIC-ERF loss. Thus, while our data support the upregulation and potential induced dependence on ETV1 in our <italic>CIC-ERF</italic> deficient systems, it remains unclear if this will translate beyond our cell-line based models into prostate cancer patients that harbor <italic>CIC-ERF</italic> co-deletions. Thus, larger studies that aim to evaluate: (1) ETV1 mRNA and protein expression levels; (2) the biological significance of ETV1 function; and (3) the clinical application of ETV1 inhibitors in patients with endogenous <italic>CIC-ERF</italic> co-deleted tumors (compared to <italic>CIC-ERF</italic> WT tumors) is warranted in this subset of PCa. Collectively, we have uncovered a molecular subset of PCa defined by a co-deletion of CIC and ERF and further demonstrate a mechanismbased strategy to potentially limit tumor progression through ETV1 inhibition in this subset of human PCa.”</p><p>Following ERG, ETV1 is the most frequently overexpressed ETS gene in prostate cancers. Prior studies (PMIDs: 16254181, 18594527, 21298110) have found both fusion dependent (<italic>ETV1</italic>-translocations) and fusion independent (increased WT <italic>ETV1</italic> transcript levels) mechanisms that can lead to increased <italic>ETV1</italic> mRNA expression in prostate cancers. Thus, increased <italic>ETV1</italic> expression can be observed in other subsets of prostate cancer beyond <italic>CIC-ERF</italic> co-deleted tumors. We suspect that our analysis comparing <italic>CIC-ERF</italic> co-deletion to <italic>CIC-ERF</italic> WT tumors did not reach statistical significance due to the inability to identify other prostate tumors that have increased <italic>ETV1</italic> expression from alternative mechanisms, beyond CIC-ERF co-deletions.</p><disp-quote content-type="editor-comment"><p>Second much of the critical data is underwhelming, does not reach statistical significance, and seems to be presented in ways intended to obscure the real results. Examples of this include the setting of every odd column to 1 and normalization of each even column to the prior odd column in Figures 5A, 5B, 5C, and 5S2B, C, E, and F – with no explanation that this is being done.</p></disp-quote><p>We have now modified the Figure title and clearly delineated the comparisons in the figure 5 legend. It now reads:</p><p>Figure 5. Combinatorial CIC and ERF loss can modulate ETV1 inhibitor sensitivity in prostate cells. (A) DU-145 cells were transfected with either siScramble (siSCM) or siCIC. After 48 hours, BRD32048 (ETV1 inhibitor) was added to both the transfected groups at the defined concentrations (0 μM, 25 μM, 50 μM). After 24 hours of BRD32048 treatment, cells were replated for crystal violet assay (0.4%) and images were taken and analyzed after 5 days (n=3). siCIC was compared to siSCRM conditions in each respective drug concentration. (B) Crystal violet viability assay (n=3). siETV1 groups were compared to siSCRM control groups +/- CIC expression (sgCtrl, sgCIC1, or sgCIC2). (C) DU-145 cells were transfected with either siScramble (siSCM) or siCIC. After 48 hours, BRD32048 was added to the transfected groups at defined concentrations (0 μM or 50 μM). Transwell invasion assays (n=3) were performed 24 hours after the addition of BRD32048. siCIC was compared to siSCRM in the 0 μM and 50 μM concentration groups. (D) Transwell invasion assays (n=3) comparing siETV1 to siSCRM control +/- CIC expression (sgCtrl, sgCIC1 or sgCIC2). P value = *p&lt;0.05, **p&lt;0.01 for all figures. Error bars represent SD.</p><p>Moreover, we now provide additional figures (Figure 5 —figure supplement 2D,E,I,J) to allow for comparisons between the PNT2 and PC-3 crystal violet assays in Figure 5 —figure supplement 2B, C, G, and H. We continue to observe a decrease in invasiveness and a milder, albeit consistent decrease in viability upon ETV1 inhibition in our engineered CIC-ERF deficient cells. We have further modified the text to highlight the shortcomings of our in vitro models and reserve claims on the potential impact on clinical translation until further studies are performed as we mention in the Discussion section.</p><disp-quote content-type="editor-comment"><p>This is also true of the ChIP control presented in the rebuttal, which includes an irrelevant input column that obscures the necessary comparison of IgG to anti-CIC and anti-ERF. It is also a problem that this control is presented in an entirely different way than the ChIP in Figure 4 that it is necessary to control for, and the control does not appear to be included in the revised manuscript.</p></disp-quote><p>We have included the ChIP control experiments into the revised manuscript as Figure 4</p><p>—figure supplement 1O-P. In addition, we quantified the <italic>ETV1</italic> ChIP-PCR performed in Figure 4 using conventional densitometry (Image J), making comparison between CIC or ERF to IgG. This has been included in the revised manuscript as Figure 4 —figure supplement 1M-N.</p></body></sub-article></article>